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Ag  Antigen 
APC   Antigen presenting cell 
BCL-2  B-cell lymphoma 2 
confluent  cell layer covering the plate 
COX-2   Cyclo-oxygenase 2 
DTZ  Dithizone (diphenylthiocarbazone) 
HO  Hoechst  
IEQ  islet equivalent 
IFN-γ  Interferon-γ 
IL- Interleukin- 
MIN6  Murine insulinoma beta-cell line 
NOD  Non-obese diabetic mouse 
NOS2A  Nitric oxide synthase 2  
PI  Propidium iodide 
RT-qPCR  Real-time quantitative polymer chain reaction 
SOD2  Superoxide dismutase 2 
T1D  Type 1 diabetes 
Th cell helper T cell    
Treg cell regulatory T cell    
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1.  INTRODUCTION 
                                                                                                          
Autoimmunity is a condition where host immune system cells destroy host cells and 
tissues. Type 1 diabetes (T1D) is one of the most prevalent autoimmune diseases. In 
T1D insulin-producing pancreatic beta cells are destroyed. Insufficient insulin release 
leads to hyperglycemia and ketonuria and causes complications when the body uses 
fats as an alternative energy source. The pathogenesis of T1D is a relatively slow 
process, and it usually starts years before the onset of the disease. 
The pathogenesis of T1D is not fully understood. Genetic and environmental factors 
are known to affect the disease development. The beta-cell destruction is widely 
accepted to be mediated by deregulated effector T cells. Excessive Th1 (Kallmann et 
al., 1997) and Th17 type immune responses (Arif et al., 2011; Honkanen et al., 2010; 
Marwaha et al., 2010), as well as impaired function of regulatory T cells (Tregs) 
(Lindley et al., 2005), have been associated with T1D both in animal models and in 
human T1D. The importance of Th1 and Th17 cells in autoimmunity is underlined by 
the fact that excessive activation of these cells has been implicated in many other 
autoimmune diseases including multiple sclerosis, rheumatoid arthritis and Chrohn’s 
disease. 
Th17 cells mediate tissue inflammation and they are important in mucosal immunity. 
Th17 cells typically secrete IL-17, IL-22 and IL-21 cytokines. IL-17 induces 
inflammation, immune cell infiltration and pro-inflammatory cytokine production 
(Mesquita Júnior et al., 2010). 
In patients with new-onset T1D, up-regulation of IL-17 and IL-22 has been detected in 
the peripheral blood. IL-17 has been found to promote proinflammatory action on 
human pancreatic cells by itself and in synergy with IL-1b and IFN-γ. It was shown to 
up-regulate gene expression of SOD2 (superoxide dismutase 2), NOS2A (nitric oxide 
synthase 2) and COX-2 (cyclo-oxygenase 2), which reflect the cell stress state. In 
addition, IL-17 was shown to down-regulate anti-apoptotic BCL-2 (B-cell lymphoma 2) 
expression, thus, predisposing beta-cells to apoptosis (Honkanen et al., 2010). Up-
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regulation of Th17-mediated immunity has firmly been associated with T1D in 
patients with new-onset T1D. 
However, the role of IL-22 is not known in T1D. IL-22 is known to have proliferation 
promoting and protecting effect in the gut associated tissue. Thus, to assess the net 
effect of the activation of Th17-immunity on the pathogenesis of T1D, the effects of 
IL-22 in cytokine mediated inflammation of beta cells need to be investigated. 
In this thesis the role of IL-22 in cytokine-mediated beta-cell destruction was studied. 
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2.   INNATE AND ADAPTIVE IMMUNITY 
                                                                                                                             
The immune system contains innate and adaptive immunity which work in a 
coordinated fashion to protect the body against pathogens. The innate system acts as 
a physical, chemical and biological first line defense. It is conserved and responsible 
for rapid protection against a broad range of invaders. The recognition is based on 
pathogen-associated molecular patterns (PAMPs) on pathogen surfaces. Those are 
identified by a conserved set of pattern recognition receptors (PRR). Different PRR’s 
are expressed mainly on phagocytes which can activate opsonisation, complement 
system and phagocytosis depending on the threat. Toll-like receptors (TLRs) are a 
family group in the PRR entity. They are expressed on macrophages, neutrophils and 
dendritic cells (DCs), and are responsible for initiating the inflammatory response. The 
weakness of innate immunity is its incapability to create new unique PRR receptors. 
The immunological response is similar each time it recognizes the same invader again 
(Cruvinel et al., 2010).  
The adaptive system is capable of more precise recognition, specific response and 
forms immunological memory against invaders. This is based on the genetic variability 
of pathogen recognition counterparts in T and B cells. T cells can recognize a specific 
antigen (Ag) peptide presented by an infected cell or antigen presenting cell (APC). 
The T-cell can directly kill the infected cell or it can cause T-cell activation and clonal 
expansion. T cells activate other immune system cells against invaders carrying 
antigen counterparts. T helper cells activate specified B cells to differentiate to 
plasma cells which produce antibodies against pathogenic structures. Antibodies can 
neutralize or destroy the pathogen with help of other immune system cells (Mesquita 
Júnior et al., 2010). 
            
2.1   Central and peripheral tolerance    
                                                                           
The immune system can distinguish foreign structures from the body’s own 
structures. This will prevent the immune system from acting against its own tissue. 
This phenomenon is called immunological tolerance (Starr et al., 2003), which is 
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divided into central tolerance and peripheral tolerance. Central tolerance develops in 
the thymus while peripheral tolerance is generated in peripheral lymphoid organs.   
The T- and B lymphocytes and NK cells originate from lymphoid progenitors from 
pluripotent stem cells in the bone marrow. The cells that migrate to the thymus are 
developing to T lymphocytes and start to express toll cell receptor (TCR). Then T cells 
undergo positive and negative selection towards peptides presented by class I or II 
major histocompatibility complex (MHC) molecules. After the selection process           
a T-cell becomes single positive, expressing either CD4 or CD8 (Mesquita Júnior et al., 
2010). 
Following the selection, T cells migrate to secondary lymphoid organs where local 
antigens are presented. T cells can be inactivated (anergy), directed to apoptosis or 
suppressed by the regulatory T cells (Tregs).  
 
The T cells escaping from negative selection from the thymus and developing to 
autoreactive T cells are suggested to be involved in beta-cell destruction. Tregs are 
known to reduce the activation of autoreactive T cells and sustain tolerance. Thus, 
they inhibit the insulitis development (Sakaguchi et al., 2008).  
                                                                                                     
2.2   Effector T cells                                                                                                             
                                                        
Effector T lymphocyte populations (Teff’-s) are morphologically similar but they 
release different mixtures of cytokines thus causing different immune responses. The 
two main populations are T-helper (CD4+ T) and cytotoxic T (CD8+ T) lymphocytes. 
Both of these populations are important in protection against pathogens. In 
inflammation CD4+ T cells activate B cells, macrophages and CD8+ T cells, and 
coordinate the immune response. CD8+ T cells act mainly in antiviral and anti-tumor 
responses. Both Th and CD8+ T cells have their TCR composed of α- and β-chains. A 
minor proportion of the T lymphocyte population has its TCR composed of γ- and δ-
chains. These γδ T cells act in skin and mucous regions and provide a link for reactions 
between innate and adaptive immunity. 
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According to current knowledge the CD4+ T cell population contains at least Th1, Th2, 
and Th17 effector T cells (Teff) and regulatory T-cell (Treg) populations. These 
subpopulations are differentiated from naive Th0 cells, initiated by stimuli from 
antigen presenting cells (APC) and the cytokine environment (Mesquita Júnior et al., 
2010). In addition, there is also a CD4+ T population which is IL-22 positive and IL-17 
negative, thus called Th22 cells (Fujita, 2013).   
  
2.3   T-helper cells 
                                                             
Th1 cells have an important role in the eradication of intracellular pathogens. Th1 
cells secrete IFN-γ that is important for inducing macrophages against intracellular 
pathogen such as viruses and mycobacteria. IFN-γ promotes the Th0 differentiation to 
Th1 pathway and suppresses Th2 pathway. It leads to T-bet expression which is Th1 
cells specific transcription factor. IL-2 is another important cytokine secreted by Th1 
cells that supports the proliferation of CD4+ T and CD8+ T cells. It also promotes the 
cytotoxic capacity of CD8+ T cells. Th1 cells have been associated with many 
autoimmune diseases (Mesquita Júnior et al., 2010).  
Th2 cells promote antibody production by producing IL-4, -5, -6 and -10. IL-4 induces 
B lymphocyte immunoglobulin class to IgE. It also supports Th2 pathway positive 
feedback and suppresses Th1 pathway. IL-5 is known to promote eosinophil 
formation and activation. GATA-3 is a specific transcription factor for Th2 
differentiation. Th2 cell function has been associated with allergic diseases and 
asthma (Mesquita Júnior et al., 2010). 
Th17 cells have their own transcription factors and characteristic secreted molecules 
(Harrington et al., 2005). Human Th17 cells express cell surface IL-23 receptor, 
chemokine receptor CCR6, lectin receptor CD161 and transcription factor retinoic 
acid-related orphan receptor C (RORC2) (Maggi et al., 2010). 
The importance of Th17-immunity is in defence against extracellular micro-organisms, 
such as, bacteria and fungi. Th17 cells produce cytokines from IL-17 family, IL-22 and 
IL-26 (Mesquita Júnior et al., 2010). Cytokines IL-17A and IL-17F protect against 
bacterial and fungal infections by inducing numerous pro-inflammatory mediators 
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such as chemokines, cytokines and metalloproteinases from epithelial and fibroblast 
cells. 
IL-17 induces inflammation, immune cell infiltration and pro inflammatory cytokine 
production (Mesquita Júnior et al., 2010). IL-17 also mediates many biological 
processes such as IL-6 and IL-8 induction from fibroblasts and Intercellular Adhesion 
Molecule 1 (ICAM-1) expression increase on fibroblasts, Nuclear Factor-KappaB     
(NF-kB) activation and T-cell proliferation. 
The up-regulation of IL-17 production has been associated with several autoimmune 
conditions such as multiple sclerosis, inflammatory intestinal disease and psoriasis 
(Mesquita Júnior et al., 2010). 
Th17 cell expresses also IL-22 cytokine. IL-22 induces epithelial cells to produce Reg 
family antimicrobial peptides, including Reg3β and Reg3γ (Zheng et al., 2008).  
  
2.4   Regulatory T cells          
        
Tregs control and adjust immune responses. Their functions are the production of 
anti-inflammatory cytokines such as IL-4, IL-10 and TGF-β and also the inhibition of 
effector cells by direct cell-cell contact. The main types of Tregs are naturally-
occurring regulatory T cells (nTregs) and peripherally induced regulatory T cells 
(iTregs) (Mesquita Júnior et al., 2010). 
nTregs develop in the thymus. Tregs express high levels of CD25 (α-chain of IL-2 
receptor) (Sakaguchi et al., 2011) and transcription factor forkhead box 3 (FoxP3). The 
latter is important for the developmental function for Tregs but it is also essential for 
the suppression function in immune responses. Mutation in the FoxP3 region 
develops IPEX (Immune dysregulation, polyendocrinopathy, enteropathy, X-linked) 
syndrome in patients. In this syndrome Treg development is impaired, resulting in 
defective suppressor function. Uncontrolled effector T cells can react against 
commensal bacteria or innocuous environmental antigens. They can cause 
autoimmune disorder affecting several organs causing allergy and intestinal 
inflammatory disease (Brunkow et al., 2001). 
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In mouse, the mutation in FoxP3 domain has been linked to scurfin protein 
dysfunction which is essential for normal immune homeostasis. In these sf mice CD4+ 
and CD8+ T cell responses are not properly regulated which leads to fatal 
lymphoproliferative disorder (Brunkow et al., 2001). 
iTreg populations differentiate in the secondary lymphoid tissues. Th3 regulatory cells 
secrete TGF-β and Tr1 cells secrete IL-10. These two cell subsets express the same 
surface molecules and low levels of CD25. FoxP3 is expressed in Th3 cells in 
stimulation but not in Tr1 cells (Vieira et al., 2004; Zheng et al., 2008).  
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3.   T1D 
                                                                                                                    
Diabetes is an organ specific disorder which covers defects in insulin secretion, 
function or both. Insulin hormone is important in glucose metabolism. Defective 
regulation of blood glucose level leads to hyperglycemia and numerous damaging 
effects of which the majority is associated to vascular damage. 
The pathogenesis of T1D is not fully understood. Genetic and environmental factors 
are known to affect the disease development. Eventually, unknown triggering events 
lead T cells of the immune system to recognize one or more beta-cell peptides as 
‘non-self’. Th cells initiate B cells to secrete autoantibodies against beta-cell antigens 
in the circulation. When the disease develops, immune cells progressively infiltrate 
into the islets (insulitis). Infiltrated T cells and macrophages cause beta-cell death by 
various mechanisms leading to insulin insufficiency. At the time of clinical 
manifestations more than 80% of an individual’s beta-cell mass has been destroyed 
(Eizirik et al., 2009).       
T1D is a chronic lifetime lasting disease. The diagnosed patient is usually a child or 
young adult. The cause of T1D is loss of insulin producing beta-cells, which leads to 
non-sufficient insulin secretion. In the more common type 1A form (T1D hereafter) 
the loss is caused by autoreactive T cells. The cause of loss in rare 1B form is 
unknown.       
  
3.1   Epidemilogy of T1D 
                                 
T1D prevalence is highest in Western societies. In Finland T1D had the highest 
incidence, 64 per 100 000 inhabitants, in the world in 2005. From the year 1980 to 
2005 the incidence has been doubled (Harjutsalo et al., 2008).  
                                                                                
Similar growth is predicted for the current decade 2010-2020 according to EURODIAB 
study (Patterson et al., 2009). Approximately half of the patients are diagnosed 
before the age of 14 years. The current acceleration of incidence has been reported     
15 
 
to be highest among the children of 0-4 years of age in several countries (Harjutsalo 
et al., 2008).          
  
3.2   Symptoms and diagnosis of T1D                                                                                                 
Diabetes causes symptoms related to hyperglycemia and osmotic diuresis. 
Incapability in glucose intake causes the body to burn fats for an energy source, 
resulting in increased keto acid levels in the blood stream. The disease is diagnosed 
when blood glucose level reaches 11.1 mM or if it persists beyond 7.0 mM in fasting 
conditions (Kahn, 2003). 
Glycated hemoglobin (HbA1c) level has been shown to correlate between the duration 
and level of hyperglycemia and glucotoxicity (Maedler et al., 2001). The HbA1c level 
increase has been found to predict both type 2 diabetes onset and T1D onset risk in 
children (Stene et al., 2006). 
A diabetic patient needs insulin supplementation for the rest of the life time. Long-
term complications of the disease can lead to extensive vascular damage, blindness, 
heart defect and chronic ulcers.             
                                                                                                 
3.3   Environmental factors of T1D 
                                                                                                                                
Many environmental factors are suspected as inducers leading to autoimmune 
diabetes. Infections caused by bacteria and viruses can trigger the immune system by 
many ways. One of these is possible pancreatic tissue damage which can expose beta-
cell epitopes to immune cells. Different chemical or physical agents such as 
pesticides, drugs or UV radiation are also thought to have the capability to cause a 
triggering effect. Nutrition, such as cow’s milk, wheat gluten and soy products are 
under suspection (Savilahti et al., 1988). In addition, climate seasonal changes are one 
possible cause because the case incidence is higher during colder winter months.  
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3.4   Genetic factors of T1D        
                                                                                                                                        
The disease accumulates in families and the genetic impact is polygenic. Over 40 
genetic loci are known to have predisposing effect to T1D (Barrett et al., 2009). The 
loci conferring most of the genetic risk for T1D is highly polymorphic Human 
Leucocyte Antigen (HLA) region. The role of peptide presenting MHC molecule (HLA in 
human) is fundamental also in other autoimmune diseases (Cruvinel et al., 2010). 
These antigen presenting molecules are divided to HLA class I and HLA class II. HLA 
class II molecules are expressed on the cell surface of antigen presenting cells (APC). 
The predisposing or protective effect of HLA class II molecule is associated with 
certain haplotypes. Haplotypes DR4 and DQ8 are known to cause the highest risk. 
HLA-DQ is a heterodimeric molecule which is coded by genes DQA1 and DQB1. HLA 
genes are highly polymorphic, which causes structural variation on molecules. This 
affects peptide binding capability and has impact on antigen presenting (Sheehy et 
al., 1989), and thus, on T-cell activation.  
Insulin gene promoter polymorphism is another factor contributing to the genetic risk 
for T1D. Its effect is associated with low expression level of insulin in the thymus at 
the time of lymphocyte negative selection (Pugliese et al., 2001; Vafiadis et al., 1997). 
As a result it could lead to defective selection of autoreactive T cells and 
miseducation of nTreg cells specific for beta-cell structures.  
In addition, polymorphism in numerous genes is known to contribute to the genetic 
risk of T1D. One of them is Cytotoxic T-lymphocyte antigen 4 (CTLA-4) which is 
expressed on CD4+ and CD8+ -T-cell surface at TCR-mediated stimulation. It maintains 
peripheral tolerance by down-regulating activated T-cells (Tivol et al., 1995) and has 
been shown to be significantly linked to T1D (Steck et al., 2005).  
Another gene, PTPN22 codes lymphoid-specific protein phosphatase (LYP) which is 
primarily expressed on helper T-cells. PTPN22 negatively regulates T-cell activation 
and one of its polymorphic variants 1858T, is associated with T1D (Zoledziewska et 
al., 2008).      
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3.5   Autoimmunity in T1D         
               
Autoantibodies against beta-cell structures can be found in T1D patient circulatory 
system in most of the cases. The autoimmunity nature of T1D was first revealed at 
mid-1960. The infiltrated immune cells were found in the inflamed islets of dead 
patients who had acute onset diabetes (Gepts, 1965). A few years later the 
pathogenicity of disease was linked to other autoimmune diseases such as thyroiditis 
and adrenalitis (Goldstein et al., 1970; Irvine et al., 1970; Nerup et al., 1970). The 
autoimmune nature of T1D was finally confirmed when T1D was linked to the HLA 
region (Nerup et al., 1974)  and the first islet cell autoantibodies (ICA’s) were found 
(Bottazzo et al., 1974; MacCuish et al., 1974).                                                                
In addition to ICA’s, other autoantibodies found to be associated with T1D include 
insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD65) and autoantibodies 
to tyrosine phosphatases IA-2 and IA-2β (Atkinson & Maclaren, 1993; Baekkeskov et 
al., 1990; Karlsen et al., 1992). Recent finding is autoantibodies to the cation efflux 
transporter ZnT8 (Wenzlau et al., 2007). 
 
3.6   Immunological aberrancies in T1D    
                                                                                                                                                               
The immune tolerance is dictated by the dynamic balance between effector T cells 
and Tregs. When this balance is disturbed the Th cells are thought to initiate 
autoimmunity and CD8+ cells to cause the final destruction of beta-cells (Bendelac et 
al., 1987; Wicker et al., 1994). Cytokines secreted by Th1 and Th17 cells are linked to 
many inflammatory and autoimmune conditions in human and animal models 
(Gysemans et al., 2008). Th2 cell population, in contrast, has been shown to protect 
against autoimmunity (Suarez-Pinzon & Rabinovitch, 2001). 
 
 
 
18 
 
3.6.1   Th1 cells and excessive IFN-ƴ secretion in the islets  
               
It was first demonstrated that purified T cells from diabetic donor NOD mice are 
effective enough for transferring diabetes to recipient (Bendelac et al., 1987). The 
importance of Th1 cell population in T1D development was shown in the NOD mouse 
study where transferred Th1 cells from diabetic NOD mouse resulted in onset of T1D 
to healthy recipient (Katz et al., 1995).                           
Research with NOD mouse model has revealed that the role of IFN-γ is controversial 
in T1D development (Hultgren et al., 1996), but it activates CD8+T cells which will 
cause beta-cell destruction (Wang et al., 1997). To support this, in the later study the 
deletion of IFN-γ in NOD mice was found to delay diabetes (Trembleau et al., 2003).                 
In another study it was shown that IFN-γ was essential in the diabetes progression in 
NOD.scid recipients. In the research the cells were differentiated from islet-reactive 
BDC2.5 TcR transgenic CD41 cells to express either Th1 or Th17 phenotype in vitro. 
Both of these cell types transferred the disease to NOD.scid recipient mice with a 
similar onset. However, there was a difference in the inflammatory process 
surrounding the islet. Th1 cells promoted islet-restricted lesions while Th17 cells 
recruited a massive infiltrate that extended to the exocrine pancreas. However, the 
recovered BDC2.5 cells from diabetic NOD.scid mice showed predominant IFN-ƴ over 
IL-17 expression in both cases (Martin‐orozco et al., 2009). 
 
3.6.2   IFN-γ secretion and function in T1D   
  
Approximately 40% of the mononuclear cells infiltrating in pancreatic island in T1D 
patient express IFN-γ (Foulis et al., 1991). The Th1 cell featuring cytokine IFN-γ has a 
dual role when signaling either STAT1-pathway (signal transducer and activator of 
transcription-1) or IRF-1 (interferon regulatory-1) pathway (Gysemans et al., 2008). 
STAT1 activation has been suggested to promote beta-cell destruction and IRF-1 
activation to predispose against IFN-γ damage. Janus kinase (JAK)/STAT1 pathway 
inhibition has been proven to prevent beta-cells from cytokine induced damage. 
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IFN-γ cytokine itself is not harmful to beta-cells but together with IL-1b or TNF-α they 
promote apoptosis. Different pathways are activated in these cytokine combinations. 
IFN-γ/TNF-α signaling is known to cause destruction through Fas/FasL pathway if 
perforin is absent (Gysemans et al., 2008). IL-1b/IFN-γ signaling activates JAK/STAT1 
pathway. IL-1b/TNF-α signaling caused cell damage through NF-kB pathway. 
       
3.6.3   Th17 immunity in T1D    
  
The role of Th17 immunity in human T1D is still unclear, while its pathogenicity has 
been linked to many autoimmune diseases such as multiple sclerosis, rheumatoid 
arthritis and inflammatory bowel disease (Crome et al., 2009; Mesquita Júnior et al., 
2010).  
Th17 immunity was demonstrated in T1D when high expression levels of IL-17 in NOD 
mice pancreas and blood stream correlated with insulitis (Vukkadapu et al., 2005).    
IL-17-producing cell differentiation was shown to require TGF-b stimuli among IL-6.  
TGF-b can suppress Th1 and Th2 differentiation (Veldhoen et al., 2006). In the later 
study Th17 polarised BDC2.5 T-cells were shown to induce the onset of diabetes in 
SCID/NOD mouse (Bending et al., 2009).  
Th17 cell role in the pathogenesis of T1D has been shown in mouse models, especially 
if these cells were converted to IFN-ƴ expressing cells (Bending et al., 2009; 
Martin‐orozco et al., 2009). In the Martin-orozco study it was demonstrated how fully 
differentiated Th17 cells could be converted to Th1 phenotype expressing cells in the 
NOD.scid mice. Th17 cells were shown to be required to promote extensive 
inflammation by IL-17 and IL-17F in the NOD mice islets, which correlated with 
insulitis and diabetes. However, their conversion to Th1 cells in NOD.scid recipient 
hosts triggered diabetes onset (Martin‐orozco et al., 2009). 
 
In another study, the Th17 function was shown to be necessary in the development of 
diabetes in NOD mice particularly during the effector phase of the disease 
pathogenesis. Th17-cell function was inhibited by anti–IL-17 or by IL-25 (IL-17E), 
which both resulted in similar implications. Development of diabetes was prevented 
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in the majority of treated animals by 6 months of age when treatment was initiated 
at 10 weeks of age. The Th17 inhibition by anti-IL-17 alone or by IL-25 alone reduced 
the islet inflammation and caused a significant diminish in peri-islet Th and CD8+ -cell 
infiltrates. In contrast, Treg population increased in the islets in both treatments. 
Moreover, GAD65 autoantibody levels were also decreased in both treatments 
(Emamaullee et al., 2009). 
Afterwards, increased Th17 immunity was found in children with recently diagnosed 
T1D (Honkanen et al., 2010; Marwaha et al., 2010). The stimulated peripheral blood 
mononuclear cells (PBMC) and memory T cells from children with T1D had up-
regulated IL-17, IL-22 and FOXP3 mRNA levels in vitro. In addition, up-regulated 
RORC2 expression and FOXP3 expression was measured from the stimulated PBMC in 
vitro and circulating memory T cells ex vivo (Honkanen et al., 2010). 
As mentioned in the previous chapter, both IL-17 and IL-22 are up-regulated 
simultaneously in the stimulated cells from patients with recent-onset T1D. However, 
the effect or function of IL-22 on beta-cells in T1D has not been reported, although, at 
least three studies have demonstrated IL-17 to be harmfull to beta-cells (Arif et al., 
2011; Grieco et al., 2013; Honkanen et al., 2010). 
It is known that the FOXP3+ Treg population suppressive effect on Th17 cells is altered 
in T1D. Particularly in humans, Th17 cells express RORC2 which is resulted from STAT3 
signaling (Ivanov et al., 2006). RORC2 down-regulates Treg development by inhibiting 
related FOXP3 pathway. Conversely, Treg specific transcription factor FOXP3 inhibits 
RORC2 transcription and settles balance to Th17/Treg –cell populations (Ono et al., 
2007; Zhang et al., 2008). The measured up-regulation of FOXP3+ cells in children 
peripheral blood memory cells can be the result of unbalance between Teff/Treg 
cells. In a later study by Ferraro et al. (2010), circulating (PB) Th17 cells were found to 
reside in pancreatic draining lymph nodes. In the same study Tregs were found to be 
epigenetically imprinted which caused their dysfunction. However, in contrast to 
previous works conducted by Honkanen et al. (2010) and Marwaha et al. (2010) with 
child patients, adult T1D patients did not show Th17 expansion in the peripheral 
blood. 
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IL-17 effect on human pancreatic cells was found to promote the proinflammatory 
action by itself and in synergy with IL-1b and IFN-γ. IL-17 in synergy with IL-1b and 
IFN-ƴ up-regulated gene expression of SOD-2, NOS2A and COX-2. IL-17 alone down-
regulated the BCL-2 expression in the beta-cells and thus predisposed them to 
apoptosis (Honkanen et al., 2010).    
   
3.6.4   CD8+ T-cells in T1D     
      
The quantity of CD8+ T-cells and insulin amount in islets has been shown to correlate 
during insulitis (Willcox et al., 2009). This suggests that autoreactive T-cells become 
redundant in the islets after beta cells are destroyed. A stydy by Kronenberg et al. 
(2012) supports earlier work by demonstrating the preproinsulin (PPI) epitope as a 
target for HLA-A24 class I molecule specific CD8+ T-cells. HLA-A24 is major 
susceptibility gene in T1D.     
  
3.7   Immune system cells and cytokines in pancreatic islet inflammation 
 
3.7.1   Pancreatic Langerhans islets    
                               
The human and mammalian pancreas consists of exocrine and endocrine divisions. 
The islets of Langerhans represent 2% of pancreas in endocrine division (Haist, 1971). 
The islets of Langerhans contain beta-cells (65-90%), alfa-cells (15-20%), delta-cells         
(3-10%) and polypeptide producing (PP) cells (1%) (Elayat et al., 1995).                                                                                                      
Beta-cells are highly specialized cells which produce storage and secrete insulin. Beta- 
cells respond to changes in glycemic level. Glucose maintains beta-cell function by 
inducing insulin production. Alpha-cells, in turn, release glucacon which induces the 
liver to release glucose into the blood stream. Delta-cells produce somatostatin, a 
growth hormone inhibiting hormone, which regulates the endocrine system. PP-cells 
act as secretion regulators both in exocrine and endocrine divisions. 
Pancreatic Langerhans islets are the only insulin secreting organ. However, 
proliferation capability of a beta-cell is low since only 1% of adult cells undergo 
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mitotic phases. Replication of beta-cells has been noticed to be highest at childhood, 
after which it slowly decreases (Menge et al., 2008). So far there is no exact 
information about human beta-cell lifespan but they have been proposed to generate 
also from stem cells in ductal epithelium (Bonner-Weir et al., 2010).  
                                                                                  
3.7.2   Cytokines secreted in insulitis 
                                                                                                                                               
Several cytokines have been shown to be involved in T1D development. Disease 
promotion is linked to cytokines Interleukin (IL)-1b, tumor necrosis factor (TNF)-α, 
TNF-β, interferon (IFN)-α, IFN-γ, IL-2, IL-6, IL-12, IL-17, IL-18, IL-21 and IL-27. Cytokines 
linked to opposite action are IL-4, IL-10 and tumor growth factor (TGF)-β (Van Belle et 
al., 2011). In addition, dual action either promoting or predisposing against disease 
development is known by cytokines IFN-γ (Gysemans et al., 2008), IL-10 and TNF-α 
(Singh et al., 2011).      
        
3.7.3   Immune cells in insulitis                                                                                      
                                      
The immune cells present in pancreatic islet inflammation include Th, CD8+, NK T-
cells, dentritic cells and macrophages (Gysemans et al., 2008). CD8+ T cells are the 
predominant immune system cell population in pancreatic islets during insulitis 
(Bottazzo et al., 1985). Macrophages were found to be the second largest group and 
Th -cells were present in every sample (Willcox et al., 2009). In the same study, B-cell 
(CD20+) amount increased during insulitis progression. However, plasma cells 
(CD138+) were found only rarely, likewise for Tregs and Natural killer (NK) cells. 
  
3.8   Beta-cell apoptosis and stress response   
                                
Apoptosis is one of the main mechanisms of beta-cell death in T1D. Apoptosis is 
programmed cell death which is regulated by extracellular signals, ATP levels, 
phosphorylation cascades and expression of pro- and anti-apoptotic genes (Eizirik & 
Mandrup-Poulsen, 2001). Several molecules including Fas ligand (FasL), perforin,   
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TNF-α, IL-1 and nitric oxidase (NO) are thought to be primary factors leading to 
activation of caspase pathway which finally leads to beta-cell apoptosis. Interaction 
with other effector molecules such as IFN-γ excites the apoptosis progression (Kim et 
al., 2012).  
The infiltrated immune cells that mediate and cause apoptosis are mainly 
macrophages, CD8+ and CD4+ T cells. CD8+ T cells can mediate beta-cell death by 
secreting perforin and granzyme which cause membrane disruption of the target cell. 
CD4+ T cells in the islets produce cytokines that trigger apoptosis through several 
signaling pathways. CD4+ T cells can activate other immune system cells such as B 
cells to produce antibodies against beta-cell structures (Mesquita Júnior et al., 2010). 
 
In normal conditions in vivo, a dead cell is digested and removed by macrophages, 
phagocytes or dendritic cells. However, a sudden increase in the rate of apoptosis can 
expose more antigenic structures exposed to immune system cells and promote the 
autoimmunity progression. This could be caused by hyperactivity in apoptotic 
mechanisms or insufficient disposal of apoptotic cells (Cruvinel et al., 2010). 
 
High cytotoxicity is caused if proinflammatory cytokines IL-1, IFN-γ, TNF-α and TNF-β 
act in combinations. In addition, combinations of these cytokines have been shown to 
reduce insulin secretion in isolated rodent and human islets (Rabinovitch, 1998). IL-1b 
and TNF-α can both activate NF-kB signaling pathway (Gysemans et al., 2008) in 
human islet cells and rodents (Eizirik & Mandrup-Poulsen, 2001). NF-kB activates 
multiple gene regulatory networks such as expression of production of nitric oxide 
synthase (iNOS) (Darville & Eizirik, 1998; Eizirik & Mandrup-Poulsen, 2001) and 
chemokines. In addition, NF-kB signaling causes endoplasmic reticulum (ER) stress by 
calcium depletion which can cause unfolded protein accumulation (Schroder & 
Kaufman, 2005). The cell death is caused by activation of mitogen-activated protein 
kinases, ER stress and the release of mitochondrial death signals (Eizirik & Mandrup-
Poulsen, 2001). 
IFN-γ signaling activates the tyrosine kinases JAK1 and JAK2 which phosphorylate the 
transcription factor STAT-1. Dimerized STAT1 translocates to the nucleus where it 
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activates multiple genes (Eizirik & Mandrup-Poulsen, 2001).  JAK/STAT signaling may 
lead to cell death. It is regulated by mechanisms such as dephosphorylation of JAK 
and cytokine receptors by SHP and inhibition of JAK by the suppressor of cytokine 
signaling (SOCS) family (Flodstrom et al., 2003; Karlsen et al., 2001). STAT1 
knockdown has been shown to protect INS-1E and primary beta-cells against cytokine 
induced apoptosis (Moore et al., 2011). 
 
The mitochondrion has an important role in triggering apoptosis (Newmeyer & 
Ferguson-Miller, 2003). Cytochrome c release from the mitochondria to the cytosol is 
considered as a key factor in apoptosis. Cytochrome c is component of the 
mitochondrial electron-transport chain and its release to the cytosol leads to 
activation of caspase-9 and -3 leading to cell death (Friedlander, 2003). BCL-2 (B-cell 
lymphoma 2) family members have been associated to protect (BCL-2, BCL-XL, Ced-9, 
BCL-w and MCL-1) or promote (Bax, BCL-XS, Bad, Bak, Bid, Bik and Bim) cell against 
apoptosis (Adams, 1998). They regulate the mitochondrial response against pro-
apoptotic signals (Newmeyer & Ferguson-Miller, 2003).  
BCL-2 protein has been localized to various organelle membranes including 
mitochondria, the nucleus and the endoplasmic reticulum (Nechushtan et al., 1999). 
It is an anti-apoptotic protein which expression has been shown to protect mouse 
(Iwahashi et al., 1996) and human (Rabinovitch et al., 1999) islets under cytokine 
induction. Bax protein acts as an antagonist for BCL-2 protein and promotes cell 
death. It is activated by apoptotic signaling which causes a conformational change in 
Bax protein and movement from cytosol to organelle membrane surface, in particular 
to mitochondria (Nechushtan et al., 1999; Wolter & Hsu 1997). 
In cell apoptosis NOS2A is up-regulated, free oxygen radicals are formed and 
apoptosis signaling pathways are activated in beta cells. The cell can protect against 
oxidative stress by expressing superoxidase dismutase (SOD2). It converts oxygen 
radicals into hydrogen peroxide which can be detoxified (Flynn & Melov, 2013). In the 
pancreatic islet cell, cyclo-oxygenase-2 (COX-2) is elevated through Nf-kB pathway in 
inflammatory or stimulated incidents. COX-2 activates inflammation mediative factor 
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Prostaglandin (PGE2) at the plasma membrane, which has been associated with cell 
dysfunction, including insulin release (Robertson, 1998). 
IL-17 alone or in combination with IL-1b/IFN-γ has been demonstrated to up-regulate 
SOD2, COX-2 and NOS2A expression in human islets. IL-17 promotes inflammation 
and increases apoptosis phenomenon. IL-17 alone was also shown to down-regulate 
BCL-2 expression in the islet cells (Honkanen et al., 2010).  
According to Arif, S et al., the cytokine combinations IL-1b/IFN-γ and TNF-α/IFN-γ 
cause STAT1 and NF-kB -apoptosis pathway activation and up-regulation of IL-17 
receptor (IL17R) expression in human islets, rat beta-cells, and INS-1E cells. IL-17 
signaling can then promote the inflammation in the cells and increase the apoptosis 
phenomenon (Arif et al., 2011).    
   
3.9   Beta-cell regeneration    
  
The maintenance of beta-cell population is the sum of rate of replication, hypo- or 
hypertrophy, apoptosis, and neogenesis from other pancreatic cell types (Jun-Li et al., 
2008). Several growth factors such as insulin-like growth factor (IGF-I), glucagon-like 
peptide 1 (GLP-1), growth hormone (GH), hepatocyte growth factor and Reg-proteins 
have been associated with islet cell proliferation (Egan et al., 2003; Jun-Li et al., 2008; 
Lingohr et al., 2002; Planas et al., 2006; Takasawa & Okamoto, 2002).  
IGF-I function has been linked to neogenesis of beta cells (Bonner-Weir, 2000; Xu et 
al., 1999). Moreover IGF-I, GLP-1 and hepatocyte growth factors have been found to 
lack the ability to maintain constant increase in beta-cell mass and function (Liu et al., 
2010). In addition, the results containing IGF-I have been controversial. IGF-I has been 
shown to induce islet growth in vitro and in transgenic mice (Liu et al., 2010). 
However, endogenously given IGF-I did not result in beta-cell growth in pancreatic-
specific IGF-I deficiency (PID) mice. Instead, IGF-I deficiency was linked to islet cell 
protection and growth. Moreover, significant and specific up-regulation of Reg genes, 
especially Reg2 and Reg3b, were found to be up-regulated in the pancreas of PID 
mouse (Jun-Li et al., 2008).   
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3.9.1   Reg proteins in the pancreas         
                                                                            
Most of the Reg proteins are expressed in a number of organs including pancreas, 
liver, intestine, and bladder (Matsumoto et al., 2012; Parikh et al., 2012). Reg proteins 
are known to induce islet growth and differentiation and protect cells from apoptosis 
(Parikh et al., 2012). Moreover, Reg2 mRNA hyper expression has been demonstrated 
to correlate with the acceleration of the development of T1D in NOD mice (Baeza et 
al., 1997; Planas et al., 2006). One of the REG family members, HIP/PAP in human, 
was also found to be over expressed in the islets of diabetic human patients. Its 
homologue in mice was characterized as an autoantigen (Gurr et al., 2002). Moreover 
REG autoantibodies have also been found in T1D patients. These antibodies were 
shown to correlate with disease duration and C-peptide levels (Shervani et al., 2004). 
Reg proteins can be divided to four classes based on DNA sequence and protein 
structure. Class 1 contains Reg1 in mouse and rat. Human have REG1α and REG1β 
homologues. Class 2 includes mouse and hamster Reg2 but no member in human. 
Class 3 members in mouse are Reg3α, Reg3β, Reg3γ and Reg3δ and in rat 
PAP/peptide 23 (p23), Reg3/PAP II and PAP III. Human members in the class 3 are 
HIP/PAP and INGAP which is homologue of the neogenesis associated protein. Reg4 is 
the only member of the class 4 in mouse, rat and human. The Reg homologues are 
common also in other species (Parikh et al., 2012). 
All Reg family mRNAs can be detected from the pancreas. Reg1 is expressed in acinar 
cells. Its expression has been detected during islet regeneration or hyperplasia 
especially after beta cell damage (Parikh et al., 2012). Reg2 is predominately 
expressed in the islet beta-cells (Gurr, 2007). Substantial Reg2 expression has been 
shown in hyperplastic but not under normal conditions in the islets. Reg3α and Reg3b 
have been detected in the pancreatic islets (Gurr, 2007). Reg4 is expressed in acinar 
cells of rat and in human beta-cells. Human REG4 mRNA expression up-regulation has 
been associated with development of pancreatic cancer (Parikh et al., 2012). 
Several studies indicate Reg protein to be involved in cell protective mechanisms. 
Reg2 effect has been demonstrated to occur after beta cell damage or stress in the 
islets of NOD mice (Parikh et al., 2012; Planas et al., 2006). Increased expression of 
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Reg2, Reg3β and Reg3ƴ has been observed in partially pancreatectomized mice 
undergoing exendin-stimulated islet cell regeneration (De León et al., 2006). Reg2 has 
also been shown to protect mouse insulinoma cells (MIN6) from streptozotocin-
induced apoptosis (Liu et al., 2010).  
Reg protein administration to partially pancreatectomized mice has been 
demonstrated to improve the condition of the animals. In the study conducted by 
Watanabe et al. particularly beta-cell islet replication was shown to increase while 
fasting plasma glucose levels decreased. In addition, Reg protein was shown to 
stimulate islet beta-cell replication in vitro as well (Watanabe et al., 1994). In another 
study, beta-cell mass of NOD mice was demonstrated to increase or to be maintained 
after Reg protein administration together with immunomodulative linomide (Gross et 
al., 1998). Moreover, transgenic Reg NOD mice have been shown to result in 
significant delay in the onset of diabetes. In contrast, the Reg knockout mice were 
observed to have smaller islet size and reduced beta-cell proliferation than controls 
(Unno et al., 2002). 
 
Significant Reg2 mRNA up-regulation, 60-200 folds, has been measured after 
Complete Freund’s adjuvant (CFA) feed stimulation. This was observed both in 
diabetic and non-diabetic mice (Huszarik et al., 2010). This adjuvant has been 
suggested to induce cytokines to activate transcription factors linked to Reg2 gene. 
In contrast to animal studies, detectable beta-cell regeneration has not been 
observed after partial pancreatectomy in human studies (Menge et al., 2008). Neither 
proliferation has been found in isolated human beta-cells in comparison to Rat beta 
cells which were shown to regenerate in vitro (Parnaud et al., 2008). 
Reg genes are regulated by many factors including inflammation. IL-6 is known to 
cause effect on Reg gene up-regulation. IL-6 expression can be promoted by IFNβ 
which can be triggered in cell stress (Planas et al., 2006).  
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3.9.2   IL-22 in Reg gene activation and in tissue repair  
  
According to several studies IL-22 activates Stat3 and up-regulates several Reg genes 
both in human and in mice. These include REG Iα, Reg2, Reg3a, Reg3b and Reg3c. 
(Aggarwal et al., 2001; Gurney, 2004; Sekikawa et al., 2010; Wolk et al., 2010). 
IL-22 is known to have impact in antimicrobial defence, cell regeneration and 
protection against cell damage. IL-22 protects the host by inducing the expression of 
antimicrobial proteins and mediators and promoting epithelial proliferation. IL-22 is 
produced most notably by Th17 cells but also other innate and adaptive immune 
system cells including Th22, Th1 and NK cells (Zenewicz & Flavell, 2011). In mice the 
Th22 is an unknown population and Th17 cells are thought to be primary producer of 
IL-22 (Wolk et al., 2010).  
 
Only a few organs express IL-22 specific receptor subunit (IL-22R1) thus being able to 
initiate IL-22 signaling. These are the skin, kidney, pancreas, small intestine, liver, 
colon, lung and trachea. Many of these act as barriers against invaders and contain 
epithelial cells. The highest amount of IL-22R1 has been measured from pancreatic 
alfa- and beta cells (Shioya et al., 2008). IL-22R is absent from immune system cells 
which indicates that IL-22 is solely a messenger from immune cells to tissue. IL-22 
signaling activates JAK-STAT pathway in the pancreas. It is driven by Jak1, Tyk2 and 
STAT3 proteins. Jak1 is linked to IL-22R1 thus being required for IL-22 signaling 
(Gurney, 2004). 
 
IL-22 signaling regulates antimicrobial peptides containing the b-defensin family 
proteins, S100 family proteins, Reg family proteins and lipocalin-2. The Reg proteins 
include RegIIIa, RegIIIb and RegIIIc (Leung & Loke, 2013). IL-22 induces also the 
release of chemokines and cytokines such as CXCL1, CXCL5, CXCL9, IL-6 and G-CSF 
(Rutz, 2013). In addition, IL-22 activates the expression of mucins which form a 
protective layer in the gastrointestinal tract (Zenewicz & Flavell, 2011).  
IL-22 has also a role in tissue repair after wounding. There are several studies of IL-22 
mechanism in tissue proliferation. In a study conducted by Feng et al. (2012), the 
protective effect of IL-22 on chronic pancreatitis was demonstrated in wild mice. The 
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mice were driven to cerulein-induced pancreatitis which was treated with 
recombinant IL-22 or adenovirus vector-IL-22. As a result, anti-apoptosis related 
genes, Bcl-2 and Bcl-X, were detected to reduce autophagosome formation which 
improved pancreatitis. 
In other in vivo mice studies IL-22 expression has been shown to provide protection 
against hepatitis (Radaeva et al., 2004; Zenewicz et al., 2007). IL-22 was shown to 
promote expression of genes involved in mitogenesis, cell transformation and anti-
apoptosis. IL-22 has also been shown to result in liver regeneration after partial 
hepatectomy in mice (Ren et al., 2010). 
IL-22 signaling has also been shown to be critical in regeneration of the damaged 
thymus in mice (Dudakov et al., 2012). In this study IL-22 mRNA level was up-
regulated in the thymys epithelial cells under thymopoiesis. After cellular recovery    
IL-22 expression was stabilized. IL-22 production was driven by IL-23 secreted by DC’s. 
In this study the thymic recovery was shown to be impaired in IL-22-deficient mice. 
Exogenous administration of IL-22 was demonstrated to improve this recovery. 
IL-22 role in chronic inflammatory disease has been associated with both protective 
and pathogenic mechanisms. Protective or inflammatory mechanism of IL-22 has 
been thought to result based on tissue and cytokine environment involved and 
inflammation context in general. IL-22 as well as IL-17 is associated in many chronic 
autoimmune diseases during inflammation. These include Systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), Sickle cell (SS) 
and psoriasis (Pan et al., 2013). IL-22 up-regulation often correlates with disease 
activity (Zenewicz & Flavell, 2011) and can be differentially expressed in many 
autoimmune diseases (Pan et al., 2013).  
Protective function of IL-22 has been found in Allergic airway inflammation. IL-22 was 
demonstrated to have immune-suppressive response in a mouse study (Nakagome et 
al., 2011). Another example is inflammatory bowel disease (IBD) where IL-22 has 
been linked to improved innate epithelial defence and mucosal barrier integrity in 
mice studies (Leung & Loke, 2013).  
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In the skin, IL-22 is involved in triggering keratinocyte proliferation, epidermal 
hyperplasia and antimicrobial protein production. IL-22 is an inhibitor for terminal 
differentiation of keratinocytes as well. There are number of skin diseases in addition 
to psoriasis where IL-22 is associated. These include atopic dermatitis (AD), contact 
dermatis (ACD), scleroderma, cutaneous T cell lymphoma (CTCL), and Squamous cell 
carcinoma (SCC). Depending on the disease, the IL-22 expressing cells Th22, Th17 and 
Th1 are shown to be present in high quantities. Secondly, IL-22 mRNA expression 
levels have been demonstrated to be up-regulated in skin lesions and IL-22 serum 
levels can be highly elevated. IL-22 function in these diseases is present but the 
mechanism is unclear (Fujita, 2013). 
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4.   HYPOTHESIS AND AIMS OF THE STUDY  
 
The study hypothesis was that IL-22 exerts a protective and proliferation promoting 
effect on beta cells in cytokine-mediated inflammation. 
In this study, the aim was to investigate the effect of IL-22 on the functioning, 
regeneration and survival of IL-1b, IFN-ƴ and IL-17 –stimulated murine beta cells 
(primary aim) and human pancreatic islets (secondary aim). 
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5.  RESEARCH METHODS AND MATERIALS   
  
5.1   MIN6-cell line     
  
Murine insulinoma -beta cell line was developed from transgenic C57BL/6 mouse 
insulinoma cells. They express Glucose transporter 2 (GLUT-2) and glucokinase as a 
glucose sensor. MIN6 cells response to glucose when nicotinamids are present. All the 
MIN6 cells originate from one individual only (Miyazaki et al., 1990).  
The cells were kindly provided by Professor Timo Otonkoski. They were stored in 
liquid nitrogen at -180 °C in 1.8 ml tubes in suspension containing 90% of fetal bovine 
serum (FBS) (Gibco, Cat. no. 10108) and 10% (V/V) of dimethyl sulfoxide (DMSO, 
Sigma, Cat. no. D8418).   
5.1.1   Cultivation and maintenance    
  
In each experiment one frozen cell line suspension tube was thawed in a 37 °C water 
bath. Content was dissolved into 5 ml of growth medium containing Dulbecco's 
Modified Eagle Medium (DNEM) (Gibco, Cat. no. 41965-039) supplemented with 10% 
(V/V) of FBS, 9 µg/ml of Pen-Strep (Gibco, Cat. numb. 15140-122) and 0.004
 µl/ml of  
β-mercaptoethanol. Cell culture media was 0.22 µm sterile-filtered (Millipore, Cat. no. 
SCGPU02RE) before use.   
Cells were harvested and pelleted with centrifugation (Heraeus instruments, Cat. no. 
315812) of 900 rpm for 5 min. Then cells were resuspended in 4 ml of media and 
divided to four wells in 24-well plate (Corning, Cat. no. 3524). Incubation conditions 
of 37 °C and 5% CO2 were in use at all steps including stimulation period and staining 
procedure. Fresh media was changed for cells every 1-3 days.  
  
5.1.2   Cell passage     
   
To maintain uncrowded and stable growth conditions, cell passaging was conducted 
when 80% confluence was reached normally in 7-10 days. In this procedure, the cells 
were rinsed twice with 1 ml of PBS (Phosphate buffered saline)(Lonza, Cat. no. BE17-
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516F) after the media was removed. Detachment treatment with 100 µl of Trypsin-
EDTA (Gibco, Cat. no. 25200-056) per well was conducted after washing the wells 
with PBS. Unmounted cells were collected together from all wells, and harvested with 
centrifugation (900 rpm, 5 min). After the centrifugation, the supernatant was poured 
off and the cells were resuspended to orginal density. Passage to wells was 
conducted in ratio of 1:4 to fresh media. For the staining of the stimulated cells 
(section 5.4), the cover slips were placed on the bottom of the well before pouring 
the suspension into the wells.    
  
5.2   Human pancreatic islet preparations   
  
Human organ tissues used in this work were donated organs. They were received 
from Clinical Islet Transplantation Consortium (CIT) in Uppsala, Sweden, led by 
Professor Olle Korsgren through the laboratory of Professor Timo Otonkoski’s Stem 
cell research center at the University of Helsinki. Three samples containing purified 
islet equivalents (IEQ)(Table 1) were used in the experiments. A share of total purified 
islets was given.     
  
Table 1. Number of islet equilevants (IEQ’s) from two samples with purity estimation 
given by CIT.  
HUMAN ISLET FRACTIONS IEQ's PURITY ARRIVAL DATE 
        
 
PREPARATION  1 35000 72 3.5.2012 
    PREPARATION 2 
 
PREPARATION 3 
35000 
 
57000 
65 
 
89 
18.9.2012 
 
1.2.2013 
          
Islets preparations were harvested in 50 ml falcons with centrifugation of 6 min and 
75 x g. Supernatant was discarded and islets were resuspended in Ham F10 (Gibco, 
Cat. no. 41550021) media and 0.5% (w/V) of HSA (human serum albumin). The 
pancreatic islet preparations were incubated on an ultra-low attachment plate 
34 
 
(Corning, Cat. no. 3262) for 3-4 days with intention to kill the exocrine cells. Media 
was exchanged after a two day period. Beta cell proportion of the islets was 
estimated (table 6) before cytokine stimulation by using Dithizone (DTZ) -staining 
method. This result was compared to given purity information by Clinical Islet 
Transplantation (CIT) Consortium in Uppsala.    
5.3   Cytokine stimulation 
5.3.1   Cytokines     
  
Recombinant cytokines (Table 2) were in lyophilized form at the time of arrival. They 
were dissolved according to the manufacturer’s (R&D Systems) instructions, aliquoted 
and stored at -70 °C until use.    
  
Table 2.  Recombinant cytokines used in experiments (R&D Systems).                                                 
      
origin Cytokine Cat. No. 
      
mouse IL-1b 401-ML 
mouse IFN-ƴ 485-MI 
mouse IL-17 421-ML 
mouse IL-22 582-ML 
human IL-1b 201-LB 
human IFN-ƴ 285-IF 
human IL-17 317-ILB 
human IL-22 782-IL 
 
5.3.2   MIN6-cell stimulation    
  
Seven different cytokine environments and one without cytokines as a negative 
control was used for the stimulation of the MIN6 cells (Table 3). Experiment was 
started before 50% confluence was reached to minimize overlapping nuclei at the 
imaging stage. Cells were passaged 1-2 times before trial. Aliquoted cytokines were 
mixed in fresh media. The media in the wells was replaced with the cytokine 
containing fresh media. Parallel wells for RT-qPCR analysis and apoptosis staining 
were cultivated for each studied environment. The cells were incubated for 72 h in 
the CO2 incubator.  
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MIN6-cells were lysed right after media removal with 350 µl of RLT-buffer (Qiagen, 
Cat.no. 74104) supplemented with 10 µl/ml of β-mercaptoethanol. Lysates were 
stored in eppendorf –tubes at -70 °C until the purification of RNA.  
  
5.3.3   Human islet –stimulation    
  
Proportional counting of beta-cell islets was conducted with Dithizone -staining 
(Section 5.4.2) before the stimulation. The 48 h stimulation was conducted on 24-well 
plate (Corning, Cat. no. 3524). Pancreatic islets were stimulated with six different 
cytokine environments and without cytokines as a negative control (Table 3).  
Stimulated human pancreatic islets were collected by transferring suspension 
containing the islets to eppendorf tubes and spun (2min, 75 x g) down in centrifuge 
(Eppendorf, Cat.no. 5424). Then the supernatant was carefully removed and the cells 
were lysed with 350 µl of RLT-buffer supplemented with 10 µl/ml of β-mercapto-
ethanol. Lysates were stored in eppendorf –tubes at -70 °C. 
 
Table 3.  Cytokine combinations used for stimulation of MIN6-cells and human 
pancreatic islets. *) Stimulation containing IL-1b/IFN-γ/IL-22 was used only for MIN6 
cell test 3-6. The concentrations (ng/ml) used are informed in the brackets. 
  
IL-1b (5) IFN-y (50) IL-17 (100) IL-22 (200) 
neg. - - - - 
stim. 1 + + - - 
stim. 2 + + + - 
stim. 3 + + + + 
stim. 4 - - + + 
stim. 5 - - + - 
stim. 6 - - - + 
   stim. 7 (* + + - + 
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5.4   Staining protocols 
5.4.1   Hoechst and propidium iodide -staining for MIN6 cells  
  
The cells attached on the cover slips (Menzel-Gläzer) were stained in the wells of the 
cell culture plate. Media was replaced with the one containing both 5 µg/ml of 
Hoechst 33258 (Sigma, Cat. no. 94403) and Propidium iodide (PI) (Sigma, Cat. no. 
P4864). The cells were incubated with the dyes for 30 minutes. Unbound dyes were 
washed away by rinsing six times with PBS. Following this, fixation was performed 
with 4% Paraformaldehyde (PFA) (LATU, Cat. no. 2273) for 20 min at room 
temperature. Cells on the cover slips were washed again three times with PBS. 
Prior to mounting the cover slips were dipped in sterile-water. Then the cover slips 
were mounted on an objective slide (Menzel-Gläzer) cell side facing the objective 
slide with a droplet of mounting media (Vectashield, Cat. no. H-1000). Compilation 
was dried on a flat platform and stored at -20°C.   
5.4.2   Dithizone –staining for human pancreatic islets  
  
To assess the proportion of beta-cell containing islets of Langerhans in human 
pancreatic islet preparations, Dithizone (DTZ) -staining was used. In the procedure    
50 mg of DTZ –powder (Sigma, Cat. no. 194832) was dissolved in 100 µl of DMSO and 
further diluted into 50 ml of Hank's buffered salt solution (Sigma, Cat. no. H8264). 
Suspension was filtered (0.45 µm) to separate crude content. 200 µl of the staining 
solvent was carefully mixed with 500 µl of islet containing suspension and incubated 
for 15 min. The proportion of beta-cell containing islets (Table 6) was estimated with 
an inverted –microscope (Olympus IX50). 
 
5.5   Microscope imaging and determination the frequency of apoptotic/dying cells
            
Microscope slides were coded before image capturing by laboratory personnel. 
Images from each sample was taken with a camera (Leica, cat. no. DFC490) integrated 
to a fluorescence microscope (Leica, Cat. no. DM4000 B). Magnification of x400 was 
used. Settings for exposure time, gain and gamma -factors were adjusted for PI-
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detecting channel before capturing the images in every six experiment series. After 
adjustment, fixed settings were particularly used at PI-detecting –channel while 
Hoechst-detecting -channel settings could be refined before every snap. To examine 
the difference in cytokine induced beta-cell death, the frequency of apoptotic 
appearance was estimated from images. They were taken from 12-15 diverse cell 
containing sections from each slide. There were approximately 200 cells in one image. 
Unclear images were disposed. Cell count including early apoptotic, late apoptotic 
and necrotic phenomenon was conducted from PC-screen with a counter clicker and 
Paint-software (MS office) tools (Figure 1). Original images were saved and slide 
coding was revealed after frequency count. Total amount of slides used, images 
captured and cell counts are informed (Table 5). Median values of each treatment in 
each experiment was used for assessment of the frequency of dying cells. 
 
Figure 1. Healthy cell nucleus and chromatin structure can be seen as dark blue color 
(HO). Early apoptosis state with condensed chromatin structure can be seen as 
intense light blue color. Late apoptosis/necrotic state with broken nuclear membrane 
structure can be seen as red color (PI). 
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5.6   RT -qPCR –protocol     
  
Gene expression analysis with RT-qPCR was carried out according to the 
manufacturer’s (Applied Biosystems) instructions. All the reagents were from the 
same company if not otherwise mentioned. 
In the process the total RNA was isolated from cell lysate and transcribed to 
complementary DNA (cDNA), synthesized by reverse transcriptase (RT)-enzyme. 
Prepared cDNA was used as template in real-time-quantitative polymer chain 
reaction. The studied target region of cDNA template was measured by qPCR. This 
amplification corresponds to an equivalent amount of messenger RNA (mRNA) from a 
certain gene. In this work we measured the relative amount of mRNA products from 
cells between the different stimulations.  
The protocol was controlled by quality control (QC), kalibrator and no-template-
control (NTC) –samples. QC-samples were prepared from human PBMCs (peripheral 
blood mononuclear cells) obtained from the Buffy Coat preparation (Finnish Red 
Cross). QC samples were used to control variation between the RNA extraction 
batches. Calibrators, both human and MIN6-cell origin, were used to control the 
inter-assay variation in the qPCR. NTC-samples, which had template replaced with 
RNAse free water, were used to detect possible contamination in the reagents used 
for cDNA synthesis or qPCR. 18S reference gene was amplified in every run as an 
RNA-level indicator.     
   
5.6.1   RNA purification      
  
Cell lysis and total RNA isolation was conducted with RNase mini kit (Qiagen, Cat.no. 
74104). Frozen cell lysates were thawed in a thermoblock (Eppendorf, Cat. no. 5355) 
for 10 min at 37 °C. Suspension was transferred to QIAshredder -tube (Qiagen, Cat. 
no. 79656) and centrifuged at 14000 g, 2 min to further homogenize the sample. 
Passed solution was precipitated with 70% (V/V) ethanol in ratio 1:1 and applied to the 
RNA binding column. The columns were centrifuged (14000 g for 2 minutes) and 
bound RNA was washed with buffers and DNA was digested by DNAse I-treatment. 
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Finally, RNA was eluted from the filter with 50 µl of RNAse free water. Concentration 
was measured with spectrophotometer (Nanodrop, Cat.no. ND-1000) before storing 
at -70 °C.      
  
5.6.2   Reverse transcription (RT)    
  
Sample RNA concentration was diluted to 25 ng/µl in case it was above the level. RNA 
was pipetted to PCR tube with reagents. Reagents that were used in protocol: 
Geneamp 10x pcr buffer II (Cat. no 4379878), MgCl 25 mM (Cat. no. 4398853), dNTP 
mix (Cat. no. 18427013), random hexamers (Cat. no. N8080127), RNAse inhibitor 
enzyme (Cat. no. N8080119), Multiscribe enzyme (Cat. no. 4311235) and DNAse free 
water (Sigma, Cat. no. W3513).  
Reverse transcription was performed with regular PCR equipment (Biometra, T-
gradient). Multiscribe reverse transcription enzyme was activated by incubating the 
reaction mix at 48°C for 30 minutes followed by inactivation at 95°C for 5 minutes. 
Then cDNA was stored at -20°C until use.   
  
5.6.3   qPCR  
 
In the procedure the mixture of cDNA template, PCR Master Mix (2X)(Cat. no. 
4367846), Gene expression Assay and RNAse free water (Sigma BPC grade water, 
W3513) was pipetted into wells of 96-well plate. Filled PCR-plate was sealed with an 
optical adhesive film (Cat.no. 4311971) and spun (3000rpm, 1min). The qPCR run was 
performed with Real time PCR (StepOne plus) equipment.  
Each run contained 40 cycles including primer annealing, complementary strand 
synthesis and complementary strand separation before enzyme denaturation. Total 
of seven mRNA products from MIN6 cells and five from human islets and reference 
gene 18S were measured in the experiments (Table 4). 
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Table 4. List of gene expression assays used in experiments.                                   
RN18S1 was used as a reference gene in all runs. Catalog                        
number for every assay was 4331182. 
Gene Origin Assay 
Reg1 mouse Mm00485651_m1 Reg1 
Reg2 mouse Mm0045653_m1 Reg2 
Reg3b mouse Mm00440616_g1 Reg3b 
BCL-2 mouse Mm00477631_m1 BCL2 
INS1 mouse Mm01950294_s1 INS1 
IL-17RA mouse Mm00434214_m1 IL17RA 
IL-17RC mouse Mm00506608_m1 IL17RC 
RN18S1 human Hs03928985_g1 RN18S1 
BCL-2 human Hs00608023_m1 BCL2 
Bax human Hs00180269_m1 BAX 
SOD2 human Hs00167309_m1 SOD2 
COX-2 human Hs00153133_m1 PTGS2 
NOS2A human Hs00167248_m1 NOS2A 
 
5.6.4   Calculation of relative copy number   
  
Relative gene expression values were calculated with comparative ddCt (difference 
between cycle threshold) –method (Livak & Schmittgen, 2001). dCt -values were 
calculated by subtracting the average Ct -value of 18s gene from the average of the    
Ct -value [dCt=Ct(target) – Ct(18S)] of each target. dCt -values were calculated for the 
samples and calibrator sample. Then the relative copy number difference between 
the calibrator and sample was calculated by formula 2-[dCt(sample)-dCt(calibrator)].                                                                                                
 
5.7   Statistical methods     
  
Both apoptosis frequencies and gene mRNA values from MIN6 replicative tests were 
tested statistically. Groupwise comparisons of medians between the treatments were 
performed with the non-parametric Friedman’s test. Pairwise comparisons of 
medians were made with the Wilcoxon signed-rank test. Statistical analysis was 
performed with SPSS 19.0 (IBM) and visualization with Graph Pad Prism 6.0 -software. 
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A p-value < 0.05 was considered significant. P-values were not adjusted for multiple 
comparisons. 
In the case of human pancreatic islets, only three islet preparations from three 
different individuals was received. To avoid making strong faulty conclusions based 
on too small number of studied individuals, p-values for the gene expression values 
obtained from cytokine stimulated pancreatic islets were not calculated. The data 
from the experimentation with human derived material is presented solely for 
descriptive purposes, and thus, must be considered exploratory by nature. 
  
5.8   Ethical considerations    
  
No additional human or animal origin sampling was conducted in this project. Human 
pancreatic islets received were excessive or defective for transplantation and directed 
for alternative use in scientific research. Human islets were donations from deceased 
persons and islets were obtained with consent from the legal next-of-kin. Human 
islets were received from Clinical Islet Transplantation (CIT) Consortium in Uppsala, 
Sweden, led by Professor Olle Korsgren. They were kindly shared with us by Professor 
Timo Otonkoski, Stem cell research center at University of Helsinki. Studies with 
human pancreatic islet preparations were approved by the local ethical committees 
in Sweden and Finland. 
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6.  RESULTS 
6.1   Apoptosis and necrosis frequencies in cytokine stimulated MIN6-cells  
 
Table 5. The counted cell numbers from six experiments. Total slide, image and cell 
quantities are informed. Approximately 15 images were captured from each slide and 
over two hundred cells were count from single image on averege. 
EXPERIMENT SLIDES IMAGES CELL QUANTITY 
    TEST 1 12 211 47809 
TEST 2 12 171 37931 
TEST 3 11 175 45501 
TEST 4 12 180 38998 
TEST 5 16 245 47460 
TEST 6 14 213 42228 
 
  
 
  
TOTAL 77 1195 259927 
 
 
6.1.1   Cytokine induced cell death, early apoptosis   
   
The frequency of early apoptotic cells in cytokine-stimulated MIN6 cells differs 
between the different cytokine treatments (n=6, p<0.001, Friedmans test). Treatment 
of MIN6 cells with IL-1b/IFN-γ increased apoptosis in comparison to untreated cells 
(median values 2.8% vs. 1.1%, p<0.05)(Figure 2). IL-17 in combination with IL-1b/IFN-γ 
resulted in fewer early apoptotic cells than stimulation by IL-1b/IFN-γ (median values 
2.2% vs. 2.8%, p<0.05)(Figure 2). Conversely, IL-22 in combination with IL-1b/IFN-γ/ 
IL-17 increased apoptosis in comparison to the cell stimulation with IL-1b/IFN-γ/IL-17 
(median values 3.7% vs. 2.2%, p<0.05) (Figure 2).  
When the MIN6 cells were stimulated with IL-1b/IFN-γ/IL-22 (n=3) no difference in 
the frequency of dying beta cells was observed in comparison to IL-1b/IFN-γ 
stimulation (median values 2.7% vs. 2.8%, p>0.05)(Figure 2). No difference was 
observed in the frequency of early apoptotic cells when MIN6 cells were stimulated 
with IL-17b/IFN/IL-17 or IL-1b/IFN-γ/IL-17/IL-22 (median values 2.2% vs. 2.7%, 
p>0.05)(Figure 2). 
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Stimulation of MIN6 cells with IL-17, IL-22 or IL-17/IL-22 did not change the frequency 
of early apoptotic cells in comparison to untreated cells (Figure 2).    
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Figure 2. The frequency of early apoptotic cells in cytokine stimulated MIN6 cells 
differs between the different cytokine treatments (n=6, p<0.001, Friedmans test). The 
median value and ranges are shown in the figures. Panel A) Stimulation of MIN6 cells 
with IL-1b/IFN-γ increased apoptosis in comparison to untreated cells (n=6, p<0.05). 
IL-17 in combination with IL-1b/IFN-γ decreased the frequency of apoptotic cells 
when compared to the cells that were stimulated with IL-1b/IFN-γ (n=6, p<0.05). IL-22 
showed a proapoptotic effect on MIN6 cells in combination with IL-1b/IFN-γ/IL-17 
(n=6, p<0.05). When the MIN6 cells were stimulated with IL-1b/IFN-γ/IL-22 no 
difference in the frequency of dying beta cells could be observed in comparison to   
IL-1b/IFN-γ stimulation (n=3, p>0.05). Panel B) Stimulation of MIN6 cells with IL-17 
and/or IL-22 did not change the frequency of dying beta cells in comparison to 
untreated cells (n=6). Median values of each treatment in each experiment was used 
for analysis. p, *<0.05. Comparisons between two groups were performed with the 
Wilcoxon signed rank test. 
 
6.1.2   Cytokine induced cell death, late apoptosis and necrosis  
  
No differences were seen in the frequency of cells in late apoptotic/necrotic state 
between different cytokine stimulations of MIN6 cells (n=6, p>0.05, Friedmans test) 
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(Figure 3). The frequencies of dying beta cells in late apoptotic/necrotic state in 
different cytokine stimulations are presented in figure 3.  
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Figure 3. No differences were seen in the frequency of cells in necrotic stage (n=6, 
p>0.05, Friedmans test). The median value and ranges are shown in the figures.     
Panel A) Stimulation with IL-1b/IFN-γ alone and in combination with IL-17 showed 
similar frequency of dying cells when compared to negative control. IL-1b/IFN-γ/IL-22 
combination was used for the stimulation in three experiments. Panel B) Cell 
treatments by IL-17 and/or IL-22 stimulations did not change the frequency of dying 
beta cells (n=6). Median values of each treatment in each experiment was used for 
analysis. 
 
6.1.3   Cytokine induced cell death, all apoptotic and necrotic cells  
  
Stimulation of MIN6 cells with IL-1b/IFN-γ increased the frequency of all apoptotic 
and necrotic cells in comparison to unstimulated cells (median values 3.0% vs. 1.5%, 
p<0.05) (Figure 4). IL-17 in combination with IL-1b/IFN-γ decreased the dying cell 
frequency in comparison to IL-1b/IFN-γ treatment (median values 2.4% vs. 3.0%, 
p<0.05) (Figure 4). Conversely, IL-22 in combination with IL-1b/IFN-γ/IL-17 increased 
apoptosis and necrosis in comparison to the cell stimulation with IL-1b/IFN-γ/IL-17 
(median values 3.6% vs. 2.4%, p<0.05) (Figure 4). 
45 
 
When the MIN6 cells were stimulated with IL-1b/IFN-γ/IL-22 no difference in the 
frequency of apoptotic and necrotic beta cells was observed in comparison to           
IL-1b/IFN-γ stimulation (median values 2.8% vs. 3.0%, (n=3), p>0.05)(Figure 4).  
Stimulation of MIN6 cells with IL-17, IL-22 or IL-17/IL-22 did not change the frequency 
of apoptotic and necrotic cells in comparison to untreated cells (Figure 4). 
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Figure 4. The frequency of early apoptotic and necrotic cells in cytokine stimulated 
MIN6 cells differs between the different cytokine treatments (n=6, p<0.001, 
Friedmans test). The median value and ranges are shown in the figures. Panel A) 
Stimulation of MIN6 cells with IL-1b/IFN-γ increased cell death in comparison to 
untreated cells (n=6, p<0.05). IL-17 in combination with IL-1b/IFN-γ decreased the 
frequency of cell death when compared to the cells that were stimulated with           
IL-1b/IFN-γ (n=6, p<0.05). IL-22 showed a pro-apoptotic effect on MIN6 cells in 
combination with IL-1b/IFN-γ/IL-17 (n=6 p<0.05). MIN6 cell stimulation with IL-1b/       
IFN-γ/IL-22 was conducted in three experiments. Panel B) Stimulation of MIN6 cells 
with IL-17 or IL-22 alone had no pro- or anti-apoptotic effect (n=6). Median values of 
each treatment in each experiment was used for analysis. p, *<0.05. Comparisons 
between two groups were performed with the Wilcoxon signed rank test. 
 
6.2   Gene expression levels in cytokine stimulated MIN6 cells  
  
All the mRNA-levels are measured from lysates collected at time point 72 h. Figures 
(in this section) represent the combined median values from experiments. Reference 
-value of the untreated cells is 1.0 in every experiment. 
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6.2.1   BCL-2 gene expression in cytokine stimulated MIN6 cells  
  
Stimulation of MIN6 cells with IL-1b/IFN-γ up-regulated BCL-2 expression in 
comparison to untreated cells (median values 1.6 vs. 1.0, p<0.05) (Figure 5). IL-17 in 
combination with IL-1b/IFN-γ increased the relative expression level of BCL-2 in 
comparison to IL-1b/IFN-γ treatment (median values 2.2 vs. 1.6, p<0.05)(Figure 5). No 
difference in the gene expression levels of BCL-2 was observed between                     
IL-1b/IFNγ/IL-17 and IL-1b/IFNγ/IL-17/IL-22 treated MIN6 cells (median values 2.2 vs. 
2.0, p>0.05)(Figure 5). IL-22 in combination with IL-1b/IFN-γ did not change the 
expression of BCL-2 when compared to IL-1b/IFN-γ stimulated MIN6 cells (median 
values 2.6 vs. 1.6, n=3, p>0.05)(Figure 5). MIN6 cell incubation with IL-17 increased 
the expression of BCL-2 in comparison to untreated cells (median values 1.5 vs. 1.0, 
p<0.05)(Figure 5). Stimulation of MIN6 cells with IL-22 or with IL-17/IL-22 did not 
change the gene expression of BCL-2 in stimulated cells (Figure 5). 
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Figure 5.  Proinflammatory cytokines up-regulate BCL-2 gene expression (n=6, p<0.05, 
Friedmans test). The median value and ranges are shown in the figures. Panel A) The 
stimulation with IL-1b/IFN-γ up-regulated the BCL-2 expression in comparison to 
negative control (n=6, p<0.05). IL-17 in combination with IL-1b/IFN-γ further 
increased the expression level of BCL-2 (n=6, p<0.05). IL-1b/IFN-γ/IL-22 stimulation 
was used in three experiments. Panel B) IL-17 alone increases the BCL-2 expression in 
MIN6 cells (n=6, p<0.05). Comparisons between two groups were performed with the 
Wilcoxon signed rank test. 
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6.2.2   Reg-family gene expression in cytokine stimulated MIN6 cells 
  
No Reg1 or Reg3β mRNA expression was observed in MIN6 cells in any of the studied 
conditions. To verify that the assays used for the qPCR were capable to amplify target 
gene, we prepared cDNA from the mouse pancreas, gut and spleen tissue derived 
control RNA (a kind gift from Professor Merja Roivainen). Only the gut tissue showed 
moderate Reg1 (Ct-cycle 28, with the threshold of 0.1) and detectable amount of 
Reg3β (Ct-cycle 34) target amplification. Determination of Reg2 was unsuccessful due 
to technical reasons. The assay that was used for the amplification of Reg2 did not 
perform correctly. 
6.2.3   Gene expression of IL-17RA and IL-17RC in cytokine-stimulated MIN6 cells
  
None of the cytokine treatments of MIN6 cells induced or inhibited IL-17RA gene 
expression in comparison to untreated MIN6 cells (p>0.05, Friedmans test)(Figure 6).  
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Figure 6. The relative mRNA level of IL-17RA from stimulated MIN6 cells (n=4). The 
median value and ranges are shown in the figures. Panel A) and Panel B) None of the 
stimulations clearly changed the expression level. IL-1b/IFN-γ/IL-22 stimulation was 
used in three experiments. 
 
IL-17RC mRNA expression was up-regulated in cytokine-stimulated MIN6 cells 
(p<0.05, Friedmans test)(Figure 7). Gene expression of IL-17RC was marginally up-
regulated in IL-1b/IFN-γ stimulated MIN6 cells when compared to untreated cells 
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(median values 1.9 vs. 1.0, p=0.07)(Figure 7). IL-17 alone and in combination with     
IL-1b/IFN-γ marginally up-regulated the IL-17RC mRNA level in comparison to 
untreated MIN6 cells (median values 1.4 vs 1.0, p=0.07 for IL-17 vs. untreated, and 
2.7 vs. 1.9, p=0.07 for IL-1b/IFN-γ/IL-17 vs. IL-1b/IFN-γ)(Figure 7). IL-22 addition to    
IL-1b/IFN-γ (median values 2.5 vs. 1.9, p=0.29) or to IL-1b/IFN-γ/IL-17 (median values 
2.6 vs. 2.5, p=0.11) did not change the IL-17RC mRNA level in stimulated cells    
(Figure 7). Stimulation of MIN6 cells with IL-17, IL-22 or IL-17/IL-22 did not change the 
gene expression of IL-17RC in stimulated cells (Figure 7). However, MIN6 stimulation 
with IL-17/IL-22 resulted in slightly lower IL-17RC gene expression than IL-17 
treatment (p=0.07). 
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Figure 7. Proinflammatory cytokines up-regulated the gene expression of IL-17RC in 
MIN6 cells (n=4, p<0.05 in Friedmans test). The median value and ranges are shown in 
the figures. Panel A) Stimulation with IL-1b/IFN-γ marginally up-regulated mRNA level 
in comparison to untreated cells (n=4, p=0.07). IL-17 in combination with IL-1b/IFN-γ 
marginally increased the IL-17RC expression in comparison to IL-1b/IFN-γ-treatment 
(n=4, p=0.07). IL-1b/IFN-γ/IL-22 stimulation was used in three experiments. Panel B) 
Stimulation with IL-17 caused marginal up-regulation of expression in comparison 
both to negative control and to IL-17/IL-22 treated cells (n=4, p=0.07). Comparisons 
between two groups were performed with the Wilcoxon signed rank test. 
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6.2.4   Preproinsulin gene expression    
  
The relative preproinsulin mRNA expression decreased in MIN6 cells stimulated with 
IL-1b/IFN-γ in comparison to untreated cells (median values 0.6 vs. 1.0,p=0.07)(Figure 
8). IL-17, IL-22 or IL-17/IL-22 in combination with IL-1b/IFN-γ did not change the 
preproinsulin gene expression (Figure 8). MIN6 cell stimulation with IL-17 showed 
marginal up-regulation of preproinsulin mRNA when compared to untreated cells 
(median values 1.4 vs. 1.0, p=0.07)(Figure 8). 
Stimulation with IL-22 alone or in combination with IL-17 did not change the 
expression of preproinsulin in comparison to untreated cells (median values 1.3       
vs. 1.0, p=0.11 for IL-22 and median values 1.2 vs. 1.0, p=0.29 for IL-17/IL-22, 
respectively). Neither did mRNA levels between IL-17 and IL-17/IL-22 treatments 
deviate from each other (p=0.14). 
n
e
g
.
IL
-1
b
/I
F
N
g
IL
-1
b
/I
F
N
g
/I
L
-1
7
IL
-1
b
/I
F
N
g
/I
L
-1
7
/I
L
-2
2
IL
-1
b
/I
F
N
g
/I
L
-2
2
0 .0
0 .5
1 .0
1 .5
2 .0
r
e
la
ti
v
e
 e
x
p
r
e
s
s
io
n
A
p = 0 .0 7
n
e
g
.
IL
-1
7
IL
-2
2
IL
-1
7
/I
L
-2
2
0 .0
0 .5
1 .0
1 .5
2 .0
r
e
la
ti
v
e
 e
x
p
r
e
s
s
io
n
B
p = 0 .0 7
 
Figure 8. The preproinsulin (Ins1) levels were significantly changed in cytokine 
stimulated MIN6 cells (n=4, p<0.05 in Friedmans test). The median value and ranges 
are shown in the figures. Panel A) Stimulation of MIN6 cells with IL-1b/IFN-γ cytokines 
marginally down-regulated preproinsulin mRNA level in comparison to untreated cells 
(n=4, p=0.07). Panel B) IL-17 stimulation marginally increased preproinsulin mRNA 
level in MIN6 cells in comparison to unreated cells (n=4, p=0.07). Comparisons 
between two groups were performed with the Wilcoxon signed rank test. 
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6.3   Gene expression in cytokine stimulated human pancreatic islets 
  
Table 6. The proportion of beta-cell islets in the human pancreatic islet preparations 
before stimulation. The islets were stained with DTZ and the proportion of zinc 
containing islets were counted. The count was compared to given purity 
measurement given by CIT. *) Counting the proportion for the preparation 3 was not 
conducted. 
Human islet sample preparation 1 preparation 2 preparation 3 
beta cell islet purity 
          
purity-%  (CIT) 72 65 89 
count proportion-%  88 75 (* 
      
 
 
6.3.1   Gene expression of beta-cell stress-related genes NOS2A, SOD2 and COX-2 in 
cytokine stimulated human pancreatic islets   
   
Gene expression levels of sress response-related genes NOS2A, SOD2 and COX-2 in 
cytokine-stimulated human pancreatic islets from three different individuals are 
presented (Figure 9.) 
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Figure 9. The combinations of cytokines IL-1b/IFN-γ/IL-17 upregulate stress response-
related genes in human pancreatic islets (n=3) after 48 h. Up-regulation of NOS2A 
(panel A), COX-2 (panel C) and SOD2 (panel E) was observed in all IL-1b/IFN-γ 
stimulated human pancreatic islets. In synergy with IL-1b/IFN-γ, IL-17 upregulated 
NOS2A, COX-2 and SOD2 expression even further in every studied individual. IL-22 did 
not show clear modulatory effect on the expression of stress-related genes in 
combination with other cytokines. Up-regulation of NOS2A (panel B), COX-2 (panel D) 
and SOD2 (panel F) was observed in every studied individual when the cells were 
stimulated with IL-17 alone or in combination with IL-22. Results are expressed as fold 
difference between treatments and untreated control. 
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6.3.2   Gene expression of BCL-2 and Bax in cytokine stimulated human pancreatic 
islets      
  
Gene expression levels of anti-apoptotic BCL-2 and pro-apoptotic Bax in cytokine-
stimulated human pancreatic islets from three different individuals are presented in 
Figure 10. 
n
e
g
.
IL
-1
b
/I
F
N
g
IL
-1
b
/I
F
N
g
/I
L
-1
7
IL
-1
b
/I
F
N
g
/I
L
-1
7
/I
L
-2
2
0 .0
0 .5
1 .0
1 .5
2 .0
r
e
la
ti
v
e
 B
C
L
-2
 e
x
p
r
e
s
s
io
n
n
e
g
.
IL
-1
7
IL
-2
2
IL
-1
7
/I
L
-2
2
0 .0
0 .5
1 .0
1 .5
2 .0
r
e
la
ti
v
e
 B
C
L
-2
 e
x
p
r
e
s
s
io
n
n
e
g
.
IL
-1
b
/I
F
N
g
IL
-1
b
/I
F
N
g
/I
L
-1
7
IL
-1
b
/I
F
N
g
/I
L
-1
7
/I
L
-2
2
0 .0
0 .5
1 .0
1 .5
2 .0
r
e
la
ti
v
e
 B
a
x
 e
x
p
r
e
s
s
io
n
n
e
g
.
IL
-1
7
IL
-2
2
IL
-1
7
/I
L
-2
2
0 .0
0 .5
1 .0
1 .5
2 .0
r
e
la
ti
v
e
 B
a
x
 e
x
p
r
e
s
s
io
n
A B
C D
 
Figure 10. Gene expression of anti-apoptotic BCL-2 and pro-apoptotic Bax in cytokine-
stimulated human pancreatic islets. Human pancreatic islets were stimulated for 48 h 
with different combinations of IL-1b/IFN-ƴ/IL-17 and IL-22 (n=3). Panel A) Stimulation 
of pancreatic islets with cytokine cocktails containing IL-1b/IFN-ƴ down-regulated 
BCL-2 in all individuals studied. Panel B) IL-17 or IL-22 did not show clear modulatory 
effect on the expression of BCL-2 in different cytokine treatments. Panels C) and D) 
None of the cytokine treatments showed clear modulatory effect on the expression 
of pro-apopotic Bax in human pancreatic islets (n=2). 
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7.  DISCUSSION  
     
In the recent years the role of Th17-immunity in T1D has intensively been studied. 
Up-regulation of IL-17 and IL-22 have been found in the peripheral blood in patients 
with recent onset T1D (Honkanen et al., 2010; Marwaha et al., 2010). The pro-
inflammatory effect of IL-17 on MIN6 cells and human islets cells has been 
demonstrated (Arif et al., 2011; Honkanen et al., 2010) but no data about the effects 
of IL-22 on IL-1b/IFN-ƴ or IL-1b/IFN-ƴ/IL-17 stimulated beta cells has been published 
so far. Thus, to assess the role of Th17-immunity in the pathogenesis of T1D, the 
effects of IL-17 and IL-22 on cytokine-mediated beta-cell death should be 
investigated. 
In this study, IL-1b/IFN-γ treatment increased apoptosis of MIN6 cells. The 
combination of cytokines IL-1b and IFN-γ is known damage to beta-cells. They 
activate Nf-kB and STAT1 transcription factors which render beta cells sensitive to    
IL-17 -mediated apoptosis by up-regulation of IL-17R (Arif et al., 2011). 
In this work, IL-17 showed anti-inflammatory effect in MIN6 cells. When the cells 
were stimulated with IL-1b/IFN-γ/IL-17, a decrease in the cell death frequency was 
seen in comparison to IL-1b/IFN-γ -stimulation. This contrasts previous results about 
the role of IL-17 in IL-1b/IFN-γ stimulated MIN6 cells. IL-17 has been demonstrated to 
cause additive beta cell death in combination with IL-1b/IFN-γ (Arif et al., 2011; 
Grieco et al., 2013; Honkanen et al., 2010).  
Interestingly, IL-22 showed pro-inflammatory properties in MIN6 cells. The increase 
of dead cell frequency was caused by IL-22 in combination with IL-1b/IFN-γ/IL-17 in 
comparison to IL-1b/IFN-γ/IL-17 –treatment. In this experimental setting, IL-22 could 
be seen as an antagonizing factor against the effect caused by IL-17. However, the 
stimulation by IL-22 alone or in combination with IL-1b/IFN-γ did not change the 
frequency of dead cells, suggesting that IL-22 signaling is only initiated when IL-17 
signaling is active. 
In the current study, the anti-apoptotic factor BCL-2 mRNA showed up-regulation in 
the MIN6 cells and down-regulation in three individual human pancreatic islets 
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stimulated with IL-1b/IFN-γ. This up-regulation of BCL-2 mRNA in MIN6 cells contrasts 
also the previous work, where the expression was down-regulated in human 
pancreatic islets (Honkanen et al., 2010). Similarly, Van (2001) showed that rat beta-
cell stimulation by IL-1b/IFN-γ down-regulated BCL-2 mRNA and Bax-omega, another 
anti-apoptotic factor, expression.  
Moreover, both anti- and pro-apoptotic pathways have been demonstrated to be 
active in the human islet cells under stress caused by cytokines (Sarkar et al., 2009). In 
the study by Sarkar et al. (2009), the combination of IL-1b, IFN-γ and TNF-α induced 
up-regulation of number of anti- and pro-apoptotic genes through the NF-kB pathway 
in the human islets. In their study BCL-2 related factor BCL2A1 mRNA expression was 
up-regulated. BCL2A1 acts as an anti-apoptotic factor and its function is to inhibit the 
release of cytochrome c, component of the mitochondrial electron-transport chain, 
from mitochondria to the cytosol (Friedlander, 2003). In comparison to the current 
study, lower cytokine concentrations for IL-1b and IFN-γ were used, in addition to a 
shorter stimulation period (Sarkar et al., 2009). This might indicate that the cells are 
responding to the cytokine signaling by priming anti-apoptotic signaling in human 
islets. However, in the current study the BCL-2 mRNA was down-regulated in the 
human pancreatic islets in IL-1b/IFN-γ treatment indicating domination of pro-
apoptotic signaling. 
In the current work, IL-17 alone and in combination with IL-1b/IFN-γ induced the  
BCL-2 mRNA up-regulation in MIN6 cells. Up-regulation of BCL-2 in cytokine-
stimulated MIN6 cells could explain the decrease in the frequency of dead cells. In 
human islets IL-17 in combination with IL-1b/IFN-γ did not show clear change in BCL-2 
expression in any of the studied individuals, but stimulation by IL-17 alone showed 
marginal down-regulation in the expression of BCL-2 in two of the three individuals 
studied.  
A protective role for IL-17 in autoimmunity has been speculated in celiac disease. In 
the study conducted by Lahdenperä et al., the BCL-2 mRNA up-regulation was seen in 
Caco-2 (human colon adenocarcinoma) cells when they were stimulated with IL-17 in 
vitro. IL-17 was suspected not to contribute to apoptosis (Lahdenpera et al., 2012). 
The current experiments with MIN6 cells gave similar results. 
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Here, IL-22 in combination with IL-1b/IFN-γ/IL-17 did not change the BCL-2 gene 
expression in either MIN6 cells or in human islets. However, the dying cell frequency 
increased in MIN6 cells. This suggests that pro-inflammatory/pro-apoptotic effects of 
IL-22 in IL-1b/IFN-γ/IL-17 stimulated MIN6 cells might be mediated by some other 
mechanism than down-regulation of BCL-2.  
This work shows that stimulation by IL-1b/IFN-γ primes anti-apoptotic mechanism in 
the stimulated MIN6 cells but it is not seen in the cytokine stimulated human islets. 
IL-17 alone and in combination with IL-1b/IFN-γ contributed this anti-apoptotic 
mechanism in MIN6 cells. 
Stimulation of human islets with IL-22 showed minor up-regulation of BCL-2 mRNA. 
However, the islet cell stimulation by IL-17/IL-22 resulted down-regulation of BCL-2 
mRNA in comparison to result from IL-17 treatment. These results indicate that there 
might be interaction between the IL-17 and IL-22 signaling pathways in the islet cells 
as well. 
In the current experiments, the pro-apoptotic factor Bax mRNA levels remained 
constant in the human islets between the stimulations. Similar unchanged Bax 
expression levels have been measured previously by Van (2001) from rat cells after     
IL-1b/IFN-γ stimulation. In the same study, the BCL-2 mRNA level and release were 
clearly decreased. According to Wolter and Hsu (1997), Bax expression levels do not 
change during apoptosis. Instead, Bax protein undergoes a conformational change 
early in the apoptosis initiated by extracellular signaling. Then Bax rapidly 
translocates from the cytosol to the mitochondria causing apoptotic activity. 
Moreover, according to Knudson and Tung (1995), increased Bax mRNA levels in mice 
result in increased cell death. 
Up-regulation of IL-17RC mRNA was observed in IL-1b/IFN-γ treated MIN6 cells in 
comparison to the untreated cells. Similarly, IL-17 alone and in combination with      
IL-1b/IFN-γ caused higher IL-17RC mRNA expression in MIN6 cells. 
Our result of IL-17 receptor promoting expression in MIN6 cells by IL-1b/IFN-γ was in 
line with research conducted by Arif et al. In their experiments, the IL-17R mRNA was 
up-regulated in human islet cells, rat beta-cells and INS-1E cells. They also showed 
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that IL-17R expression requires both STAT1 and Nf-kB activation, and thus, IL-1b/   
IFN-γ stimulation. IL-1b and IFN-γ therefore renders beta cells to IL-17-mediated 
apoptosis (Arif et al., 2011).  
In the current study, the preproinsulin gene expression was down-regulated by half in 
the MIN6 cells that were stimulated with cytokine cocktails containing IL-1b/IFN-γ. 
This indicates that pro-inflammatory cytokine milieu clearly affects the primary 
function of MIN6 cells.  
There are other similar studies where IL-1b in combinations of IFN-γ and TNF-α has 
been shown to suppress insulin secretion and impair cell viability (Corbett et al., 
1993; Eizirik et al., 1994; Hostens et al., 1999). In the study by Corbett et al. the 
insulin secretion was shown to decrease when the human islet cells were stimulated 
for 24-48 h with combination of cytokines IL-1b, IFN-γ and TNF-α. According to study 
by Eizirik et al., a 55% decrease in the insulin release was seen in the cells after 6 day 
exposure to cytokines. In their study, human and rodent islets were stimulated for 48 
h with IL-1b/IFN-ƴ/TNF-α. As a result, rodent islets showed beta cell dysfunction, 
decreased insulin accumulation in the medium, impaired insulin response to glucose 
and decreased rates of glucose oxidation. In contrast, human islets showed increased 
insulin accumulation into the culture medium, preserved levels of insulin release and 
normal glucose oxidation rates (Eizirik et al., 1994). The current study with MIN6 cells 
is in line with the study conducted by Eizirik et al.  
Hostens et al. demonstrated that stimulation of human islet cell with IL-1b/IFN-γ for    
72 h resulted in slower conversion of proinsulin to insulin. Simultaneously, the 
secretory activity was shown to be higher during stimulation period. This caused 
increased amount of proinsulin and decreased amount of insulin secreted. According 
to their study the level of proinsulin content did not decrease during stimulation 
period (Hostens et al., 1999). 
Marginal down-regulation of preproinsulin mRNA in MIN6 cells under IL-1b/IFN-γ 
stimulation in the current study could be considered as a protection against immune 
system cells as well. Insulin is an important antigen in diabetes both in human and 
NOD mice models (Eizirik et al., 2009). Half of the beta cell protein production 
consists of insulin. During stress, insulin accumulates in the ER in a misfolded 
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configuration (Scheuner & Kaufman, 2008) which might increase its antigenicity 
(Eizirik et al., 2008). Decrease in antigen concentration may decrease antigen specific 
autoimmunity. In the current study, IL-17 treatment alone marginally increased gene 
expression of preproinsulin level in MIN6 cells. If IL-17 signaling would cause beta 
cells to produce more insulin, they could become more susceptible against the attack 
by autoreactive T cells. The effect may also be mediated by antigen presenting 
immune cells. However, results regarding the effects of IL-17 on the functioning of 
the beta cells need to be interpreted with caution because of the relatively low 
number of repeated experiments. 
There are studies about characteristic MIN6-cell gene expression. According to 
Roderigo-Milne et al. (2002), the two insulin genes in rodents, ins1 and ins2, can show 
differential expression levels in MIN6 cells after multiple passaging. In their study Ins1 
gene showed more than 10-fold lower expression than ins2 and was more glucose 
responsive. This indicates ins1 and ins2 are differentially regulated in the cells. It has 
also been shown that the secretion of insulin can decrease after numerous passaging 
(Cheng et al., 2012). In the work conducted by Cheng et al. it was shown that the 
metabolic profile was differentiating during numerous passaging. In the current study 
we measured the gene ins1 from the MIN6 cells. Based on these studies the ins2 gene 
measurement should be considered as well. In addition, the gene expression study 
conducted by Nakashima et al. showed that MIN6 cells produces also other hormones 
such as glucagon, somatostatin, PP and ghrelin. MIN6 cells represent not only beta 
cells, but also features of other endocrine islet cells (Nakashima et al., 2009).  
In this study the human islet cell stimulation with IL-1b/IFN-γ caused high increase in 
the NOS2A, SOD-2 and COX-2 mRNA levels in every studied individual. This was in line 
with the previous studies (Honkanen et al., 2010; Sarkar et al., 2009). In the study by 
Sarkar et al. the human islets were stimulated with IL-1b/IFN-γ/TNF-α which caused 
up-regulation of NOS2, COX-2 and SOD2. 
It has been shown that IL-17 together with IL-1b, IFN-γ and TNF-α in combinations 
stimulate iNOS (inducible NO synthase) expression and NO release in MIN6 cells and 
mouse pancreatic islets (Miljkovic et al., 2005). Eizirik et al. have shown that 
stimulation of isolated human and rodent islets with IL-1b/IFN-γ/TNF-α is powerful 
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combination of cytokines to induce iNOS up-regulation and NO production. Alone 
none of these cytokines increased NO production (Eizirik et al., 1994). 
These results indicate that IL-17 acts as a pro-inflammatory factor in human islet cells. 
NO mediates cytokine-induced rodent beta cell dysfunction and damage and is 
known to decrease insulin biosynthesis and secretion in the beta cells (Miljkovic et al., 
2005). SOD2 is an enzyme which converts reactive oxygen species (ROS) into 
hydrogen peroxide, thus protecting the cell against damage (Flynn & Melov, 2013). 
COX-2 is associated with beta cell dysfunction through activation of prostaglandin, an 
inflammation mediating factor (Robertson, 1998). 
Nitric oxide production has been shown to increase in the cells during the 
inflammation (Arif et al., 2011), which has been linked more in necrosis rather than 
apoptosis (Eizirik & Mandrup-Poulsen, 2001). In the present work, NO production was 
not measured in the experiments with MIN6 cells. However, the necrotic 
phenomenon was not notable in different cytokine environments. Early apoptosis 
was the major type of cell death in these experiments with MIN6 cells. 
In this work IL-22 did not change gene expression of the stress related genes in any of 
the studied cytokine treatments in the human pancreatic islets. Stimulation of human 
pancreatic islets with IL-22 alone caused only marginal to multi-fold up-regulation of 
NOS2A, COX-2 and SOD2 gene expression in the stimulated islets. 
No significant Reg1 or Reg3b mRNA expression was observed in MIN6 cells in any of 
the studied conditions. To verify that the assays used for the qPCR were capable to 
amplify target gene, we prepared cDNA from the mouse pancreas, gut and spleen 
tissue. Only the gut tissue showed moderate amount of Reg1 (Ct-cycle 28, with the 
threshold of 0.1) and detectable amount of Reg3β (Ct-cycle 34) target amplification. 
These results verify that our gene expression assays used for the amplification of 
Reg1 and Reg3β were working properly, and thus, the fact that we could not detect 
Reg1 or Reg3β transcripts in MIN6 cells can be considered as a true negative 
observation. Unfortunately, the assay used for the amplification of Reg2 gave 
constantly technically poor results. Therefore, we were not able to examine Reg2 
gene expression in cytokine stimulated MIN6 cells. 
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IL-22 is known to activate STAT3 and up-regulate many Reg genes both in mouse and 
human (Aggarwal et al., 2001; Gurney, 2004; Wolk et al., 2010). The highest IL-22R 
level has been measured from alfa- and beta cells in the pancreas (Aggarwal et al., 
2001; Gurney, 2004). Reg2 is predominantly expressed on beta-cell region in the 
pancreas (Gurr, 2007) and according to several studies Reg2 has been linked to 
growth stimulation of pancreatic cells (Baeza et al., 1997; Gurr, 2007; Planas et al., 
2006). Therefore, Reg2 measurent should be considered in future studies. It is of vital 
interest to understand which molecules and pathways are driven by IL-22 signaling. 
In this work, MIN6 cells and human pancreatic islets were shown to be useful tools 
for studying cytokine-mediated cell death and inflammation. The dying cell median 
value for untreated MIN6 cells was 1.5%, and for stimulated cells - maximum median 
value for stimulated cells was 3.6 % of dying cells. This was at a moderately low level 
in comparison to other studies (Arif et al., 2011; Delaney et al., 1997), indicating 
conditions that resulted in low background apoptosis in the current study. In a human 
islet study conducted by Arif et al. a high level of apoptosis was observed. After 48 h 
stimulation the proportion of dying cells was 15% with the untreated and 40% with 
the IL-1b/IFN-γ/IL-17 -stimulated cells (Arif et al., 2011). In the study conducted by 
Delaney et al., the human islets were stimulated with cytokines for three, six and nine 
days. After three days apoptosis was detected in 3.9% of untreated cells and 20% of 
cytokine-treated cells. The measurements at six and nine days showed a huge 
increase in the proportion of apoptotic cells (Delaney et al., 1997).  
The model for cytokine-mediated inflammation in MIN6 and human pancreatic islets 
cells was working in this study. In addition to changes in the frequency of apoptotic 
cells in the cytokine treated MIN6 cells, IL-17 had an effect on several genes in 
cytokine-treated human pancreatic islets. These genes included: inflammation 
associated factors and anti-apoptotic factor BCL-2. IL-22 had only minimal effects on 
the cytokine treated human pancreatic islets in the studied individuals. The change in 
the apoptosis frequency in MIN6 cells caused by IL-1b/IFN-γ, IL-1b/IFN-γ/IL-17 and    
IL-1b/IFN-γ/IL-17/IL-22 was clearly seen. However, the mechanism of action of IL-17 
and IL-22 in MIN6 cells and human pancreatic islets needs to be studied in the future 
experiments. One possible approach might be analysis of global gene expression in 
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cytokine-stimulated MIN6 cells with microarray or RNA-sequencing. Naturally, 
assessment of the effect of IL-17 and IL-22 in different combinations with IL-1b/IFN-γ 
and possibly with TNF-α on the cytokine-mediated cell death of human pancreatic 
beta cells needs to be done by studying the induction of apoptosis in the cells in the 
future. In many studies TNF-α has been used in combinations with IL-1b and IFN-γ 
(Eizirik et al., 1994; Gysemans et al., 2008; Hostens et al., 1999; Kim et al., 2012; Liang 
et al., 2006; Sarkar et al., 2009). As mentioned earlier, IFN-γ and TNF-α together 
cause the strongest viability loss of human islet cells (Kim et al., 2012). This was 
explained by IFN-γ signaling which causes cell vulnerability for TNF-α signaling, 
leading to apoptosis. However, the current study did not focus only on the induction 
of apoptosis. In addition, the stimulation periods and additional detections and 
measurements at earlier time points should be considered again in the following 
studies. 
The isolated human islets have been demonstrated to be more resistant against the 
effects of cytokines and NO (Eizirik et al., 1994) and streptozotocin (Welsh et al., 
1991) than isolated rodent islets. However, they show similar sensitivity to 
peroxynitrile which is a radical formed by NO and superoxide (Delaney et al., 1996). In 
contrast, human islets are more susceptible than rodent islets to the deleterious 
effects of high glucose (Eizirik et al., 1992). Moreover, the comparison on the species 
sensitivity to cytokines is interfered by the lack of a systematic dose response and 
time course analysis (Eizirik et al., 1994). 
This study has several limitations due to a variety of reasons. Pathogenic mechanisms 
contributing to the development of T1D are difficult to study due to many reasons. 
One of them is the long non-symptom period before the diagnosis, which can take 
many years. On the other hand, the consequences of the immune activation on the 
function and survival of the target tissue needs to be studied with target tissue or 
some other equivalent in vitro system. Research with human samples is difficult 
because of the limited avaibility of endocrine tissue. The drawbacks for the biopsy 
sampling are the anatomical location of the pancreas and complications caused by 
sampling.  
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The pancreases from deceased persons are first directed to organ transplantation. 
Only being redundant for a certain period of time they can be used in scientific 
experimentation. Another challenge in working with human tissue is the maintenance 
of the organ’s natural function. The viability of the islets impairs after prolonged 
culturing at 37 oC. In addition, heterogeneity of individual sample content can bring 
variability to studies. This provides the rationale for the use of animal and cell models 
in the research of T1D. 
The human islets in this work were donations originated from three individuals. All 
the preparates had high beta-cell islet content, over 75% before stimulation. The 
MIN6 cells used in this work originate from one primary strain. This means that the 
results obtained from the beta-cell line should be considered to be originated from 
single individual or clonal individuals. One important limitation in the interpretation 
of the results obtained from the experiments with the MIN6 cells is the nature and 
history of these cells. MIN6 cell line was established more than two decades ago and 
since that the cells have been passaged numerous times. The passaging may change 
the properties of the cells over time. In addition to unknown passaging history, the 
cancerous nature of the cells may have had an effect on results achieved in these in 
vitro experiments. 
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8.   CONCLUSIONS     
  
In this study IL-17 and IL-22 was demonstrated to modulate the outcome of IL-1b and 
IFN-γ induced stress response in mouse beta-cells and human pancreatic islets as 
measured by the changes in the frequency of apoptotic cells and gene expression of 
stress, function and cytokine-signaling related genes. Results from the experiments 
with mouse beta-cells contrasted our study hypothesis and were, at least in part, 
contradictory with earlier reports about the role of IL-17 in cytokine induced stress 
responses in beta-cells. Results from the experiments with human pancreatic islets 
needs to be interpreted with caution because of the very limited number of studied 
individuals. These results, however, are extremely useful when designing the future 
experimentation regarding the role of IL-22 in cytokine-mediated inflammation of 
pancreatic beta-cells. However, the results in the current study are promising and the 
discrepancy between these data and previously reported observations may simply 
reflect the very complex nature of cytokine signaling networks. 
The role of IL-22 in the induction of apoptosis, regeneration, stress response and 
function in cytokine-mediated stress response of beta cells remains to be elucidated 
in the future studies. In these studies, experiment conditions need to be re-evaluated 
in detail. At least cytokine concentrations and incubation times need to be evaluated. 
In addition, global gene expression analysis of cytokine-stimulated beta-cells and 
human pancreatic islet could reveal the pathways affected by IL-22. More 
importantly, the effects of IL-22 on cytokine induced cell death need to be studied 
with a greater number of human pancreatic islets from different individuals. 
 
 
 
 
 
63 
 
ACKNOWLEGEDMENTS    
  
I want to thank Professor Outi Vaarala, the head of Immune response unit, for giving 
me this opportunity for this study. I highly appreciate the facilities, materials and 
funding for this project supplied. Special thanks go to PhD Jarno Honkanen, who 
supervised this work. You gave me numerous educative and encouraging speeches 
during this study through multiple challenges. I also thank Professor Timo Otonkoski 
from the Stem cell research center at the University of Helsinki for fruitful 
collaboration regarding the studies with the human pancreatic islets. For making 
these studies possible, I want to thank Professor Olle Korsgren, the head of the 
Clinical Islet Transplantation (CIT) Consortium in Uppsala Sweden for providing 
unique biological research material for this study. I want also to thank always friendly 
and open-minded members of the Immune response unit who always fulfilled the 
atmosphere with positive mood. This work was financially supported by the Finnish 
Diabetes Research Foundation. In final words, I’m grategul to my wife, Minna and 
members of my closest family for mental and loving support.  
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
REFERENCES 
Adams, J. M. (1998). The bcl-2 protein family: Arbiters of cell survival. Science, 281(5381), 1322-
1326. 
Aggarwal, S., Xie, M. H., Maruoka, M., Foster, J., & Gurney, A. L. (2001). Acinar cells of the 
pancreas are a target of interleukin-22. Journal of interferon and cytokine research, 21(12), 
1047-1053.  
Arif, S., Moore, F., Marks, K., Bouckenooghe, T., Dayan, C. M., Planas, R., ... Peakman, M. (2011). 
Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune 
diabetes and promotes cytokine-mediated β-cell death. Diabetes, 60(8), 2112-2119.  
Atkinson, M. A., & Maclaren, N. K. (1993). Islet cell autoantigens in insulin-dependent diabetes. 
Journal of Clinical Investigation, 92(4), 1608-1616.  
Baekkeskov, S., Aanstoot, H., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., . . . De Camilli, 
P. (1990). Erratum: Identification of the 64K autoantigen in insulin-dependent diabetes as the 
GABA-synthesizing enzyme glutamic acid decarboxylase. Nature, 347(6295), 782. 
Baeza, N., Sanchez, D., Vialettes, B., & Figarella, C. (1997). Specific reg II gene overexpression in 
the non-obese diabetic mouse pancreas during active diabetogenesis. FEBS Letters, 416(3), 364-
368.  
Barrett, J. C., Clayton, D. G., Concannon, P., Akolkar, B., Cooper, J. D., Erlich, H. A., . . . Nierras, C. 
(2009). Genome-wide association study and meta-analysis find that over 40 loci affect risk of 
type 1 diabetes. Nature Genetics, 41(6), 703-707.  
Bendelac, A., Carnaud, C., Boitard, C., & Bach, J. (1987). Syngeneic transfer of autoimmune 
diabetes from diabetic NOD mice to healthy neonates. requirement for both L3T4 and lyt-2 T 
cells. The Journal of Experimental Medicine, 166(4), 823-832.  
Bending, D., De La Peña, H., Veldhoen, M., Phillips, J. M., Uyttenhove, C., Stockinger, B., & 
Cooke, A. (2009). Highly purified Th17 cells from BDC2. 5NOD mice convert into Th1-like cells in 
NOD/SCID recipient mice. The Journal of Clinical Investigation, 119(3), 565-572.  
Bonner-Weir, S. (2000). Islet growth and development in the adult. Journal of Molecular 
Endocrinology, 24(3), 297-302. 
Bonner-Weir, S., Li, W. C., Ouziel-Yahalom, L., Guo, L., Weir, G. C., & Sharma, A. (2010). Beta-cell 
growth and regeneration: Replication is only part of the story. Diabetes, 59(10), 2340-2348.  
Bottazzo, G. F., Dean, B. M., McNally, J. M., MacKay, E. H., Swift, P. G. & Gamble, D. R. (1985). In 
situ characterization of autoimmune phenomena and expression of HLA molecules in the 
pancreas in diabetic insulitis. New England Journal of Medicine, 313(6), 353-360. 
Bottazzo, G. F., Florin-Christensen, A., & Doniach, D. (1974). Islet cell antibodies in diabetes 
mellitus with autoimmune polyendocrine deficiencies. Lancet, 2(7892), 1279-1283. 
65 
 
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S. A., ... Ramsdell, 
F. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal 
lymphoproliferative disorder of the scurfy mouse. Nature Genetics, 27(1), 68.  
Cheng, K., Delghingaro-Augusto, V., Nolan, C. J., Turner, N., Hallahan, N., Andrikopoulos, S., & 
Gunton, J. E. (2012). High passage MIN6 cells have impaired insulin secretion with impaired 
glucose and lipid oxidation. Plos One, 7(7), 1-12. 
Corbett, J. A., Sweetland, M. A., Wang, J. L., Lancaster, J. R., & McDaniel, M. L. (1993). Nitric 
oxide mediates cytokine-induced inhibition of insulin secretion by human islets of langerhans. 
Proceedings of the National Academy of Sciences of the United States of America, 1993,90(5), 
1731-1735. 
Crome, S., Wang, A., & Levings, M. (2009). Translational Mini‐Review series on Th17 cells: 
Function and regulation of human T helper 17 cells in health and disease. Clinical & 
Experimental Immunology, 159(2), 109-119.  
Cruvinel, W. M., Júnior, D. M., Araújo, J. A. P., Catelan, T. T. T., de Souza, A. W. S., da Silva, N. P., 
& Andrade, L. E. C. (2010). Immune system - part I fundamentals of innate immunity with 
emphasis on molecular and cellular mechanisms of inflammatory response. Revista Brasileira 
De Reumatologia, 50(4), 434-461. 
Darville, M. I. & Eizirik, D. L. (1998). Regulation by cytokines of the inducible nitric oxide 
synthase promoter in insulin-producing cells. Diabetologia, 41(9), 1101-1108.  
De León, D.,D., Farzad, C., Crutchlow, M. F., Brestelli, J., Tobias, J., Kaestner, K.H., & 
Stoffers, D. A. (2006). Identification of transcriptional targets during pancreatic growth after 
partial pancreatectomy and exendin-4 treatment. Physiological Genomics, 24(2), 133-143.  
Delaney, C. A., Tyrberg, B., & Eizirik, D. L. (1996). Similar sensitivity of human and rat pancreatic 
islets to peroxynitrite-mediated cell dysfunction and death. Diabetologia, 39, 31.  
Delaney, C. A., Pavlovic, D., Hoorens, A., Pipeleers, D. G., & Eizirik, D. L. (1997). Cytokines induce 
deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. 
Endocrinology, 1997, 138(6), 2610-2614. 
Dudakov, J. A., Hanash, A. M., Jenq, R. R., Young, L. F., Ghosh, A., Singer, N. V., ... Marcel, R. M.  
(2012). Interleukin-22 drives endogenous thymic regeneration in mice. Science, 336(6077), 90-
95.  
Egan, J. M., Bulotta, A., Hui, H., & Perfetti, R. (2003). GLP-1 receptor agonists are growth and 
differentiation factors for pancreatic islet beta cells. Diabetes Metabolism Research and 
Reviews, 19(2), 115-123.  
Eizirik, D. L., Korbutt, G. S., & Hellerström, C. (1992). Prolonged exposure of human pancreatic 
islets to high glucose concentrations in vitro impairs the beta-cell function. Journal of Clinical 
Investigation, 1992, 90(4), 1263-1268. 
66 
 
Eizirik, D. L., Sandler, S., Welsh, N., Cetkovic-Cvrlje, M., Nieman, A., Geller, D.A., ...  Hellerström, 
C. (1994). Cytokines suppress human islet function irrespective of their effects on nitric oxide 
generation. Journal of Clinical Investigation, 93(5), 1968-1974. 
Eizirik, D. L. & Mandrup-Poulsen, T. (2001). A choice of death--the signal-transduction of 
immune-mediated beta-cell apoptosis. Diabetologia, 44(12), 2115-2133.  
Eizirik, D. L., Colli, M. L., & Ortis, F. (2009). The role of inflammation in insulitis and beta]-cell 
loss in type 1 diabetes.(report). Nature Reviews Endocrinology, 5(4), 219-226.  
Eizirik, D. L. , Cardoza, A. K., & Cnop, M. (2008). The role for endoplasmic reticulum stress in 
diabetes mellitus. Endocrine Reviews, 29(1), 42-61. 
Elayat, A. A., El-Naggar, M., & Tahir, M. (1995). An immunocytochemical and morphometric 
study of the rat pancreatic islets. Journal of Anatomy, 186(3), 629-637. 
Emamaullee, J. A., Davis, J., Merani, S., Toso, C., Elliott, J. F., Thiesen, A., & Shapiro, A. M. J. 
(2009). Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes, 58(6), 
1302-1311. 
Feng, D., Park, O., Radaeva, S., Wang, H., Yin, S., Kong, X., ... Gao, B (2012). Interleukin-22 
ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. 
International Journal of Biological Sciences, 8(2), 249. 
Ferraro, A., Socci, C., Stabilini, A., Valle, A., Monti, P., Piemonti, L., … Battaglia, M. (2011). 
Expansion of Th17 cells and functional defects in T regulatory cells are key features of the 
pancreatic lymph nodes in patients with type 1 diabetes. Diabetes, 60(11), 2903-2913.  
Flodstrom, M., Tsai, D.,  Fine, C.,  Maday, A., & Sarvetnick, N. (2003). Diabetogenic potential of 
human pathogens uncovered in experimentally permissive & beta-cells. Diabetes, 52(8), 2025-
2035.  
Flynn, J. M. & Melov, S. (2013). SOD2 in mitochondrial dysfunction and neurodegeneration. 
Free Radical Biology & Medicine, 62, 4-12. 
Foulis, A. K., McGrill, M., & Farquharson, M. A. (1991). Insulitis in type 1 (insulin-dependent) 
diabetes mellitus in man-macrophages, lymphocytes, and interferon-gamma containing cells. 
Journal of Pathology, 165(2), 97-103.  
Friedlander, R. M. (2003). Apoptosis and caspases in neurodegenerative diseases. New England 
Journal of Medicine, 348(14), 1365-1375.  
Fujita, H. (2013). The role of IL-22 and Th22 cells in human skin diseases. Journal of 
Dermatological Science, 72(1), 3-8.  
Gepts, W. (1965). Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes, 
14(10), 619-633.  
67 
 
Goldstein, D. E., Drash, A., Gibbs, J., & Blizzard, R. M. (1970). Diabetes mellitus: The incidence of 
circulating antibodies against thyroid, gastric, and adrenal tissue. The Journal of Pediatrics, 
77(2), 304-306. 
Grieco, F. A., Moore, F., Vigneron, F., Santin, I., Villate, O., Marselli, L., ... Marchetti, P. (2013).      
IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. 
Diabetologia,57(3),502-511.  
Gross, D. J., Weiss, L., Reibstein, I., van den Brand, J., Okamoto, H., Clark, A., & Slavin, S. (1998). 
Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced 
immunoregulation combined with reg protein treatment. Endocrinology,139(5), 2369-2374. 
Gurney, A. L. (2004). IL-22, a Th1 cytokine that targets the pancreas and select other peripheral 
tissues. Int Immunopharmacol, 4(5), 669-677.  
Gurr, W., Yavari, R., Wen, L.,  Shaw, M., Mora, C., Christa, L., & Sherwin, R. S. (2002).  A reg 
family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts 
as T-cell autoantigen in NOD mice. Diabetes, 51(2), 339-346.  
Gurr, W. (2007). RegII is a beta-cell protein and autoantigen in diabetes of NOD mice. Diabetes, 
56(1), 34-40. 
Gysemans, C., Callewaert, H., Overbergh, L., & Mathieu, C. (2008). Cytokine signalling in the 
beta-cell: A dual role for IFNgamma. Transactions, 36(3), 328-333.  
Haist, R. E. (1971). Functions of the islets of langerhans. Canadian Medical Association Journal, 
105(9) 
Harjutsalo, V., Sjöberg, L., & Tuomilehto, J. (2008). Time trends in the incidence of type 1 
diabetes in finnish children: A cohort study. The Lancet, 371(9626), 1777-1782. 
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & 
Weaver, C. T. (2005). Interleukin 17–producing CD4 effector T cells develop via a lineage 
distinct from the T helper type 1 and 2 lineages. Nature Immunology, 6(11), 1123-1132.  
Honkanen, J., Nieminen, J. K., Gao, R., Luopajarvi, K., Salo, H. M., Ilonen, J., … Vaarala, O. (2010). 
IL-17 immunity in human type 1 diabetes. Journal of Immunology, 185(3) 1959-1965.  
Hostens, K., Pavlovic, D., Zambre, Y., Ling, Z., Van Schravendijk, C., Eizirik, D. L., & Pipeleers, D. 
G. (1999). Exposure of human islets to cytokines can result in disproportionately elevated 
proinsulin release. Journal of clinical investigation, 104(1), 67-72.  
Hultgren, B., Huang, X., Dybdal, N., & Stewart, T. A. (1996). Genetic absence of γ-interferon 
delays but does not prevent diabetes in NOD mice. Diabetes, 45(6), 812-817. 
Huszarik, K., Wright, B., Keller, C., Nikoopour, E., Krougly, O., Lee-Chan, E., ... Singh, B. (2010). 
Adjuvant immunotherapy increases β cell regenerative factor Reg2 in the pancreas of diabetic 
mice. Journal of Immunology, 185(9), 5120. 
68 
 
Irvine, W. J., Clarke, B. F., Scarth, L., Cullen, D. R., & Duncan, L. J. (1970). Thyroid and gastric 
autoimmunity in patients with diabetes mellitus. Lancet, 2(7665), 163-168. 
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., ... Littman, D. R. 
(2006). The orphan nuclear receptor RORγt directs the differentiation program of 
proinflammatory IL-17 + T helper cells. Cell, 126(6), 1121-1133.  
Iwahashi, H., Hanafusa, T., Eguchi, Y., Nakajima, H., Miyagawa, J., Itoh, N., ... Matsuzawa, Y. 
(1996). Cytokine-induced apoptotic cell death in a mouse pancreatic beta-cell line: Inhibition by 
bcl-2. Diabetologia, 39(5), 530-536. 
Jun-Li L., Wei, C., Bing, L., & Yarong, L. (2008). Possible roles of reg family proteins in pancreatic 
islet cell growth. Endocrine, Metabolic & Immune Disorders - Drug Targets, 8(1), 1-10.  
Kahn, R. (2003). Follow-up report on the diagnosis of diabetes mellitus: The expert committee 
on the diagnosis and classifications of diabetes mellitus. Diabetes Care, 26(11), 3160-3167. 
Kallmann, B. A., Hüther, M., Tubes, M., Feldkamp, J., Bertrams, J., Gries, F. A., ... Kolb, H. (1997). 
Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and 
toward humoral immunity in graves' disease. Diabetes, 46(2), 237-43. 
Karlsen, A. E., Hagopian, W. A., Petersen, J. S., Boel, E., Dyrberg, T., Grubin, C. E., ... Lernmark, A. 
(1992). Recombinant glutamic acid decarboxylase (representing the single isoform expressed in 
human islets) detects IDDM-associated 64,000-M(r) autoantibodies. Diabetes, 41(10), 1355. 
Karlsen, A. E., Ronn, S. G., Lindberg, K., Johannesen, J., Galsgaard, E. D.,  Pociot, F., ... Billestrup, 
N. (2001). Suppressor of cytokine signaling 3 (SOCS-3) protects beta-cells against interleukin-1 
beta- and interferon-ƴ –mediated toxicity. Proceedings of the National Academy of Sciences of 
the United States of America, 98(21), 12191.  
Katz, J. D., Benoist, C., & Mathis, D. (1995). T helper cell subsets in insulin-dependent diabetes. 
Science, 268(5214), 1185. 
Kim, S., Kim, K. A., Suk, K., Kim, Y. H., Oh, S. H., Lee, M. K., ... Lee, M. S. (2012). Apoptosis of 
human islet cells by cytokines. Immune Network, 12(3), 113-117.  
Knudson, C. M. & Tung, K. S. K. (1995). Bax-deficient mice with lymphoid hyperplasia and male 
germ cell death. Science, 270(5233), 96.  
Kronenberg, D., Knight, R. R., Estorninho, M., Ellis, R. J., Kester, M. G., De Ru, A., & Peakman, M. 
(2012). Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the 
susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill ß-cells. 
Diabetes, 61(7), 1752-1759. 
Lahdenpera, A. I., Holtta, V., Ruohtula, T., Salo, H. M., Orivuori, L., Westerholm-Ormio, M., … 
Vaarala, O. (2012). Up-regulation of small intestinal interleukin-17 immunity in untreated 
coeliac disease but not in potential coeliac disease or in type 1 diabetes. Clinical & Experimental 
Immunology, 167(2), 226-234.  
69 
 
Leung, J. M. & Loke, P. (2013). A role for IL-22 in the relationship between intestinal helminths, 
gut microbiota and mucosal immunity. International Journal for Parasitology, 43(3-4), 253-257.  
Liang, S. C., Tan, X., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, 
L. A. (2006). Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively 
enhance expression of antimicrobial peptides. Journal of Experimental Medicine, 203(10), 2271-
2279. 
Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peatman, M., & Tree, T. I. M. (2005). Defective 
suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes, 54(1), 
92-99. 
Lingohr, M. K., Buettner, R., & Rhodes, C. J. (2002). Pancreatic beta-cell growth and survival--a 
role in obesity-linked type 2 diabetes? Trends in Molecular Medicine, 8(8), 375-384.  
Liu, L., Liu, J. L., & Srikant, C. B. (2010). Reg2 protects mouse insulinoma cells from 
streptozotocin-induced mitochondrial disruption and apoptosis. Growth Factors, 28(5), 370-
378.  
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time 
quantitative PCR and the 2-ΔΔCT method. Methods, 25(4), 402-408. 
MacCuish, A., Irvine, W., Barnes, E., & Duncan, L. (1974). Antibodies to pancreatic islet cells in 
insulin-dependent diabetics with coexistent autoimmune disease. The Lancet, 304(7896), 1529-
1531.  
Maedler, K., Spinas, G. A., Lehmann, R., Sergeev, P., Weber, M., Fontana, A., ... Donath, M. Y. 
(2001). Glucose induces beta-cell apoptosis via upregulation of the fas receptor in human islets. 
Diabetes, 50(8), 1683-90.     
Maggi, L., Santarlasci, V., Capone, M., Peired, A., Frosali, F., Crome, S. Q., ... Annunziato, F. 
(2010). CD161 is a marker of all human IL‐17‐producing t‐cell subsets and is induced by RORC. 
European Journal of Immunology, 40(8), 2174-2181.  
Martin‐orozco, N., Chung, Y., Chang, S. H., Wang, Y. H., & Dong, C. (2009). Th17 cells promote 
pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after 
conversion into Th1 cells. European Journal of Immunology, 39(1), 216-224.  
Marwaha, A. K., Crome, S. Q., Panagiotopoulos, C., Berg, K. B., Qin, H., Ouyang, Q., ... Tan, R. 
(2010). Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 
diabetes. Journal of Immunology, 185(7), 3814-3818.  
Matsumoto, S., Konishi, H., Maeda, R., Kiryu-Seo, S., & Kiyama, H. (2012). Expression analysis of 
the regenerating gene (reg) family members reg-IIIβ and reg-IIIγ in the mouse during 
development. Journal of Comparative Neurology, 520(3), 479-494.  
Menge, B. A., Tannapfel, A., Belyaev, O., Drescher, R., Müller, C., Uhl, W., ...  Meier, J. J. (2008). 
Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. Diabetes, 
57(1), 142-149.  
70 
 
Mesquita Júnior, D., Araújo, J. A. P., Catelan, T. T. T., de Souza, A. W. S., Cruvinel, W. M., 
Andrade, L. E. C., & da Silva, N. P. (2010). Immune system - part II basis of the immunological 
response mediated by T and B lymphocytes. Revista Brasileira De Reumatologia, 50(5), 552-
580. 
Miljkovic, D., Cvetkovic, I., Momcilovic, M., Maksimovic-Ivanic, D., Stosic-Grujicic, S., & 
Trajkovic, V. (2005). Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity 
in mouse beta cells. Cellular and Molecular Life Sciences, 2005, 62(22), 2658-68.  
Miyazaki, J., Araki, K., Yamato, E., Ikegami, H., Asano, T., Shibasaki, Y., ... Yamamura, K. (1990). 
Establishment of a pancreatic β cell line that retains glucose-inducible insulin secretion: Special 
reference to expression of glucose transporter isoforms. Endocrinology, 127(1), 126-132. 
Moore, F., Naamane, N., Colli, M. L., Bouckenooghe, T., Ortis, F., Gurzov, E. N.,  ... Eizirik, D. L. 
(2011). STAT1 is a master regulator of pancreatic {beta}-cell apoptosis and islet inflammation. 
The Journal of Biological Chemistry, 286(2), 929-41. 
Nakagome, K., Imamura, M., Kawahata, K., Harada, H., Okunishi, K., Matsumoto, T., … Dohi, M. 
(2011). High expression of IL-22 suppresses antigen-induced immune responses and 
eosinophilic airway inflammation via an IL-10-associated mechanism. Journal of Immunology, 
187(10), 5077-89.  
Nakashima, K., Kanda, Y., Hirokawa, Y., Kawasaki, F., Matsuki, M., & Kaku, K. (2009). MIN6 is not 
a pure beta cell line but a mixed cell line with other pancreatic endocrine hormones. Endocrine 
Journal, 56(1), 45-53.  
Nechushtan, A., Smith, C. L., Yi-Te, H. & Youle, R. J. (1999). Conformation of the bax C-terminus 
regulates subcellular location and cell death. EMBO Journal, 18(9), 2330-41.  
Nerup, J., Bendixen, G., & Binder, C. (1970). Autoimmunity in diabetes mellitus. Lancet, 1970, 
2(7673), 610-11. 
Nerup, J., Platz, P., Andersen, O. O., Christy, M., Lyngsoe, J., Poulsen, J. E., ... Svejgaard, A. 
(1974). HL-A antigens and diabetes mellitus. Lancet, 2(7885),     864-66. 
Newmeyer, D. D. & Ferguson-Miller, S. (2003). Correction to mitochondria: Releasing power for 
life and unleashing the machineries of death. Cell, 112(6), 873. 
Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., ... Sakaguchi, S. 
(2007). Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature, 
446(7136), 685-689.  
Pan, H. F., Li, X. P., Zheng, S. G., & Ye, D. Q. (2013). Emerging role of interleukin-22 in 
autoimmune diseases. Cytokine& Growth Factor Reviews, 24(1), 51-57.  
Parikh, A., Stephan, A. F., & Tzanakakis, E. S. (2012). Regenerating proteins and their expression, 
regulation, and signaling. Biomolecular Concepts, 3(1), 57-70. 
71 
 
Parnaud, G., Bosco, D., Berney, T., Pattou, F., Kerr-Conte, J., Donath, M. Y., ... Halban, P. A. 
(2008). Proliferation of sorted human and rat beta cells. Diabetologia, 51(1), 91-100.  
Patterson, C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009). Incidence trends for 
childhood type 1 diabetes in europe during 1989-2003 and predicted new cases 2005-20: A 
multicentre prospective registration study. Lancet, 373(9680), 2027-33.  
Planas, R., Alba, A., Carrillo, J., Puertas, M. C., Ampudia, R., Pastor, X., ... Vives-Pi, M. (2006). Reg 
(regenerating) gene overexpression in islets from non-obese diabetic mice with accelerated 
diabetes: Role of IFNβ. Diabetologia, 49(10), 2379-87. 
Pugliese, A., Brown, D., Garza, D., Murchison, D., Zeller, M., Redondo, M., ... Ricordi, C. (2001). 
Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus 
and peripheral lymphoid organs. Journal of Clinical Investigation, 107(5), 555-564.  
Rabinovitch, A. (1998). An update on cytokines in the pathogenesis of insulin-dependent 
diabetes mellitus. Diabetes/Metabolism Reviews, 14(2), 129-151. 
Rabinovitch, A., Suarez-Pinzon, W., Strynadka, K., Ju, Q., Edelstein, D., Brownlee, M., ... Rajotte, 
R. V. (1999). Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) 
protects beta-cells from cytokine-induced destruction. Diabetes, 48(6), 1223.  
Radaeva, S., Sun, R., Pan, H. N., Hong, F., & Gao, B. (2004). Interleukin 22 (IL-22) plays a 
protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via 
STAT3 activation. Hepatology, 39(5), 1332-42.  
Ren, X., Hu, B., & Colletti, L. M. (2010). IL-22 is involved in liver regeneration after hepatectomy. 
American Journal of Physiology. Gastrointestinal and Liver Physiology, 298(1), G74-80.  
Robertson, R. P. (1998). Dominance of cyclooxygenase-2 in the regulation of pancreatic islet 
prostaglandin synthesis. Diabetes, 47(9), 1379-83. 
Roderigo-Milne, H., Hauge-Evans, A. C., Persaud, S. J., & Jones, P. M. (2002). Differential 
expression of insulin genes 1 and 2 in MIN6 cells and pseudoislets. Biochemical & Biophysical 
Research Communications, 296(3), 589.  
Rutz, S. (2013). IL-22, not simply a Th17 cytokine. Immunological Review journal, 252(1), 116.  
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008). Regulatory T cells and immune 
tolerance. Cell, 133(5), 775-787.  
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (2011). Pillars article: Immunologic 
self-tolerance maintained by activated T cells expressing IL-2 receptor alpha -chains (CD25). 
breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. 
Journal of Immunology, 186(7), 3808-21. 
Sarkar, S. A., Kutlu, B., Velmurugan, K., Kizaka-Kondoh, S., Lee, C. E., Wong, R., ... Pugazhenthi, 
S. (2009). Cytokine-mediated induction of anti-apoptotic genes that are linked to nuclear factor 
72 
 
kappa-B (NF-kappaB) signalling in human islets and in a mouse beta cell line. Diabetologia, 
52(6), 1092-1101. 
Savilahti, E., Akerblom, H. K., Tainio, V. M., & Koskimies, S. (1988). Children with newly 
diagnosed insulin dependent diabetes mellitus have increased levels of cow's milk antibodies. 
Diabetes Research (Edinburgh, Scotland), 7(3), 137-40. 
Scheuner, D. & Kaufman, R. J. (2008). The unfolded protein response: A pathway that links 
insulin demand with beta-cell failure and diabetes. Endocrine Reviews, 2008, 29(3), 317-33. 
Schroder, M. & Kaufman, R. J. (2005). ER stress and the unfolded protein response. Mutation 
Research: Fundamental & Molecular Mechanisms of Mutagenesis, 569(1), 29-63.  
Sekikawa, A., Fukui, H., Suzuki, K., Karibe, T., Fujii, S., Ichikawa, K., ... Fujimori, T. (2010). 
Involvement of the IL-22/REG ialpha axis in ulcerative colitis. Laboratory Investigation, 90(3), 
496-505.  
Sheehy, M. J., Scharf, S. J., Rowe, J. R., Neme, d. G., Meske, L. M., Erlich, H. A., & Nepom, B. S. 
(1989). A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -
DQ alleles. Journal of Clinical Investigation, 83(3), 830-35. 
Shervani, N. J., Takasawa, S., Uchigata, Y., Akiyama, T., Nakagawa, K., Noguchi, N., ... Okamoto, 
H.  (2004). Autoantibodies to REG, a beta-cell regeneration factor, in diabetic patients. 
European Journal of Clinical Investigation, 34(11), 752-758.  
Shioya, M. M., Andoh, A., Kakinoki, S., Nishida, A., & Fujiyama, Y. (2008). Interleukin 22 receptor 
1 expression in pancreas islets. Pancreas, 36(2), 197-199. 
Singh, B., Nikoopour, E., Huszarik, K., Elliott, J. F., & Jevnikar, A. M. (2011). Immunomodulation 
and regeneration of islet beta cells by cytokines in autoimmune type 1 diabetes. Journal of 
interferon and cytokine research, 31(10), 711-719.  
Starr, T. K., Jameson, S. C., & Hogquist, K. A. (2003). Positive and negative selection of T cells. 
Annual Review of Immunology, 21(1), 139. 
Steck, A. K., Bugawan, T. L., Valdes, A. M., Emery, L. M., Blair, A., Norris, J. M., ... Eisenbarth, G. 
S. (2005). Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes, 54(8), 
2482-86.  
Stene, L. C. , Barriga, K., Hoffman, M., Kean, J., Klingensmith, G., Norris, J. M., ...  Rewers, M. 
(2006). Normal but increasing hemoglobin A1c levels predict progression from islet 
autoimmunity to overt type 1 diabetes: Diabetes autoimmunity study in the young (DAISY). 
Pediatric Diabetes, 7(5), 247-253. 
Suarez-Pinzon, W., & Rabinovitch, A. (2001). Approaches to type 1 diabetes prevention by 
intervention in cytokine immunoregulatory circuits. International Journal of Experimental 
Diabetes Research, 2(1), 3-17. 
73 
 
Takasawa, S. & Okamoto, H. (2002). Pancreatic beta-cell death, regeneration and insulin 
secretion: Roles of poly(ADP-ribose) polymerase and cyclic ADP-ribose. International Journal 
Experimental Diabetes Research, 3(2), 79-96.  
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995). 
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, 
revealing a critical negative regulatory role of CTLA-4. Immunity, 3(5), 541-547.  
Trembleau, S., Penna, G., Gregori, S., Giarratana, N., & Adorini, L. (2003). IL-12 administration 
accelerates autoimmune diabetes in both wild-type and IFN-γ-deficient nonobese diabetic 
mice, revealing pathogenic and protective effects of IL-12-induced IFN-γ. Journal of 
Immunology, 170(11), 5491-5501.  
Unno, M., Nata, K., Noguchi, N., Narushima, Y., Akiyama, T., Ikeda, T., ... Okamoto, H. (2002). 
Production and characterization of reg knockout mice: Reduced proliferation of pancreatic ß-
cells in reg knockout mice. Diabetes, 51, S478-83. 
Vafiadis, P., Bennett, S. T., Todd, J. A., Nadeau, J., Grabs, R., Goodyer, C. G., ... Polychronakos, C. 
(1997). Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 
locus. Nature Genetics, 15(3), 289-292.  
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011). Type 1 diabetes: Etiology, 
immunology, and therapeutic strategies. Physiological Reviews, 91(1), 79-118.  
Van, d. C. (2001). Cytokine-mediated apoptosis in rat beta-cells is preceded by downregulation 
of bcl-2 and bax-omega expression. Diabetes, 2001, 50(90001), 82S. 
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006). TGF-beta in 
the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-
producing T cells. Immunity, 24(2), 179.  
Vieira, P. L., Christensen, J. R., Minaee, S., O'Neil, E. J., Barrat, F. J., Boonstra, A., ... O'Garra, A. 
(2004). IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory 
function to naturally occurring CD4+CD25+ regulatory T cells. Journal of Immunology, 172(10), 
5986-93. 
Vukkadapu, S. S., Belli, J. M., Ishii, K., Jegga, A. G., Hutton, J. J., Aronow, B. J., & Katz, J. D. 
(2005). Dynamic interaction between T cell-mediated β-cell damage and β-cell repair in the run 
up to autoimmune diabetes of the NOD mouse. Physiological Genomics, 21(2), 201-211.  
Wang, B., André, I., Gonzalez, A., Katz, J. D., Aguet, M., Benoist, C., & Mathis, D. (1997). 
Interferon-γ impacts at multiple points during the progression of autoimmune diabetes. 
Proceedings of the National Academy of Sciences of the United States of America, 94(25), 
13844-49. 
Watanabe, T., Yonemura, Y., Yonekura, H., Suzuki, Y., Miyashita, H., Sugiyama, K., ... Kondo, H. 
(1994). Pancreatic beta-cell replication and amelioration of surgical diabetes by reg protein.  
Proceedings of the National Academy of Sciences, 91(9), 3589-3592.  
74 
 
Welsh, N., Eizirik, D. L., Bendtzen, K., & Sandler, S. (1991). Interleukin-1 beta-induced nitric 
oxide production in isolated rat pancreatic islets requires gene transcription and may lead to 
inhibition of the krebs cycle enzyme aconitase. Endocrinology, 129(6), 3167-73. 
Wenzlau, J. M., Juhl, K., Yu, L., Moua, O., Sarkar, S. A., Gottlieb, P., ... Hutton, J. C. (2007). The 
cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. 
Proceedings of the National Academy of Sciences of the United States of America, 104(43), 
17040. 
Wicker, L. S. L., Leiter, E. H., Todd, J. A., Renjilian, R. J., Peterson, E., Fischer, P. A., ...Peterson, L. 
B. (1994). Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. 
Diabetes, 43(3), 500-504. 
Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., & Morgan, N. G.(2009). Analysis of islet 
inflammation in human type 1 diabetes. Clinical & Experimental Immunology, 155(2), 173-181. 
Wolk, K., Witte, E., Witte, K., Warszawska, K., & Sabat, R. (2010). Biology of interleukin-22. 
Semin Immunopathology, 32(1), 17-31.  
Wolter, K. G. & Hsu, Y. T. (1997). Movement of bax from the cytosol to mitochondria during 
apoptosis. Journal of Cell Biology, 139(5), 1281.  
Xu, G., Habener, J. F., & Bonner-Weir, S. (1999). Exendin-4 stimulates both beta-cell replication 
and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in 
diabetic rats. Diabetes, 48(12), 2270.  
Zenewicz, L. A., Yancopoulos, G. D., Valenzuela, D. M., Murphy, A. J., Karow, M., & Flavell, R. A. 
(2007). Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute 
liver inflammation. Immunity, 27(4), 647-659.  
Zenewicz, L. A. & Flavell, R. A. (2011). Recent advances in IL-22 biology. International 
Immunology, 23(3), 159-163.  
Zhang, F., Meng, G., & Strober, W. (2008). Interactions among the transcription factors Runx1, 
RORγt and Foxp3 regulate the differentiation of interleukin 17–producing T cells. Nature 
Immunology, 9(11), 1297. 
Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., ... de Sauvage, F. J. (2008). 
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. 
Nature Medicine, 14(3), 282-289.  
Zheng, S. G. (2008). The critical role of TGF-beta1 in the development of induced Foxp3+ 
regulatory T cells. International Journal of Clinical and Experimental Medicine, 1(3), 192-202. 
Zoledziewska, M. M., Perra, C., Orru, V., Moi, L., Frongia, P., Congia, M., ... Cucca, F. (2008). 
Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 
diabetes. Diabetes, 57(1), 229.  
